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1 Abstract  
Cancer is one of the leading causes of death worldwide. In 2018, the International 
Agency for Research on Cancer (IARC) recorded 18.1 million new cancer cases and 
a mortality rate of 9.6 million cancer deaths with rising incidence. In 2040, an increase 
of 61.7% is expected compared to 2018. Treatment of cancer depends on type and 
stage, and treatment modalities range from surgery, radiotherapy, chemotherapy and 
hormone therapy to targeted therapy which can be used as single treatments or in 
combination. Most recently, immunotherapy has shown great promise to treat or cure 
cancer, immune cells can reach tissues where surgery is impossible and can even 
treat microscopic diseases or disseminated metastases. There are several types of 
immunotherapies including ones using tumor-specific immune cells (“cell therapy”) to 
attack cancer cells, or those which enhance already existing tumor-specific immune 
responses in the body.   
In my thesis, two different tumor mouse models mimicking natural tumor development 
were used to investigate the role of innate and adaptive immune cells, like NK cells 
and CD8+ T cells, in natural tumor immune surveillance. We observed that tumor 
development in mice generally led to activation of the differentiation and activity of NK 
cells. However, sustained stimulation of NK cells by tumor cells resulted in the 
generation of terminally-differentiated CD27low NK cells with diminished anti-tumor 
capacities. While IL-15 treatment of mice promoted the development of these specific 
immune cell subsets, it led to the exhaustion of NK cells. In turn, tumor development 
did not alter the distribution of CD8+ T cell subsets and naïve CD8+ T cells were the 
predominant subpopulation over time. Only the treatment of mice with IL-15 led to 
accumulation of terminally-differentiated central memory T cells which were also 
characterized by low cytotoxicity and reduced cytokine production. Taken together, 
tumor cells that develop naturally in a spontaneous cancer model are able to evade 
immune destruction by promoting the generation of immune cells with low anti-tumor 
activities. Treatment of mice with IL-15 boosts the immune system, but accumulation 
of terminally-differentiated immune cells with an exhausted phenotype lead to the 
ultimate inefficiency of this cytokine treatment and to uncontrolled development of 
tumors and metastases.  
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2 Introduction 
2.1 Cancer and metastasis 
2.1.1 Development and characteristics 
Noncommunicable diseases (NCDs) are the main cause of death worldwide. They are 
defined as persistent medical conditions resulting from genetic, environmental and 
physiological alterations. Besides cardiovascular and respiratory diseases, as well as 
diabetes, cancer is one of the main four types of NCDs1. In 2018, the International 
Agency for Research on Cancer (IARC) recorded 18.1 million new cancer cases and 
a mortality rate of 9.6 million cancer deaths worldwide. Lung, breast, colorectal, 
prostate and stomach cancer are the five most commonly diagnosed cancer types. 
Breast cancer represents the highest incidence in females (24.2%) in comparison to 
lung (14.5%) and prostate (13.5%) cancer in males2. Many factors can lead to cancer 
development. Genetic disorders, chemical and physical carcinogens, like ionizing 
radiation and UV light, but also bacteria, viruses or parasites can cause a malignant 
neoplasm3.   
Hanahan and Weinberg proposed six significant characteristics of cancer cells in “The 
Hallmarks of Cancer” in 20004. They comprise sustained proliferative signaling, 
evasion from growth suppressors, resistance to cell death, replicative immortality, 
induction of angiogenesis and activation of invasion and metastasis5. Tumor 
metastases are actually the primary cause of cancer morbidity and mortality (90%) 
versus the primary tumor itself. In 2011, Hanahan and Weinberg extended these 
hallmarks with two additional characteristics: cancer cells are able to reprogram their 
energy metabolism and can evade destruction by the immune system (Fig.1)5.   
In a process, called angiogenesis, tumors can trigger the formation of new blood 
vessels. Detached cells can develop a mesenchymal-like phenotype (epithelial 
mesenchymal transition, EMT) and use the formed blood or lymphatic system to 
intravasate from tumor sites to surrounding tissues6,7. After evading the immune 
system and surviving in the circulation, these potentially “metastatic” cells adhere to 
vessel walls and extravasate in distant organs. Only <0.01% of circulating tumor cells 
overcome selection and are able to reactivate their proliferation and form new blood 
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vessels to provide the growing macroscopic tumor8-11. The most common sites of 
cancer spreading are lung, liver and bone. In 1889, Steven Paget already postulated 
that the spread of metastasis is not random into any organ. The “seed” (tumor cells) 
and the “soil” (organ) have to be compatible. The target organ or tissue where tumor 
cells with metastatic potential migrate must provide a proper microenvironment5,12,13.
   
Since many years there is discussion as to how metastases form, resulting in two 
different models: the linear and the parallel progression models.  In the linear model, 
disseminated tumor cells (DTCs) spread from late stage primary tumors, acquire 
genetic mutations and migrate into distant sites of the body. On the contrary, in the 
parallel progression model, DTCs detach early from first primary tumor lesions and 
develop as metastases in parallel with the primary tumor14. 
  
 
Figure 1: Hallmarks of Cancer postulated by Hanahan and Weinberg in 2000 and 2011(modified from 4,5). 
15 
 
 
2.1.2 Treatment of cancer 
Treatment of cancer is dependent of the type, location and stage of disease and has 
to be decided individually. There are many forms of treatment like surgery, 
radiotherapy, chemotherapy, hormone therapy or targeted therapy. The general 
problem of cancer treatment is that many patients remain asymptotic in early stages of 
the disease, and early signs and symptoms of cancer when they do occur are ignored. 
Thus, the tumor can spread undisturbed in different parts of the body, called 
“secondary or metastatic sites”. Treatments of patients with metastatic cancer often fail 
while because primary tumors are indeed sensitive to radiotherapy or chemotherapy, 
metastases are more resistant to cytotoxic agents or cannot be precisely localized to 
be cut out15. Moreover, chemotherapy and radiotherapy have many severe side effects 
including non-specific effects on surrounding healthy tissues16.   
Immunotherapy became attractive and promising over the last few years. Endogenous 
immune cells can reach tissues where surgery is impossible and can even treat 
microscopic diseases and disseminated metastasis. Furthermore, immunotherapy 
offers long-term treatment in comparison to chemotherapy or radiotherapy that have 
effects only at the time they are being applied; the immune system has memory and 
often persists for a lifetime. The functions and activities of relevant immune cells is the 
main subject of this thesis work and will be concentrated on in the remaining part of 
this introductory section. There are several types of immunotherapies including ones 
using tumor-specific immune cells to attack cancer cells, or ones which generally 
enhance already existing tumor-specific immune responses in the body. Discussed 
below are some of the main immunotherapy approaches:  
Monoclonal antibodies (mABs) made in laboratories are specific antibodies 
recognizing proteins, such as cancer cells. After binding tumor-associated proteins, 
immune cells are attracted and can bind the mABs via their Fc receptors. Afterwards, 
immune cells are capable of killing cancer cells in a process called antibody-dependent 
cell-mediated cytotoxicity (ADCC)17. Classically, natural killer (NK) cells are the main 
immune cell population which recognizes Fc domains of mABs. Secretion of perforin 
and granzymes by activated NK cells lyse tumor cells resulting in release of tumor 
antigens which are taken up by antigen-presenting cells (APCs).  
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Tumor antigens are presented on major histocompatibility complex (MHC) molecules 
to cytotoxic T cells (CTLs) which leads to activation of the CTLs and destruction of 
tumor cells18. Furthermore, B cells are stimulated by the presented tumor antigens, 
resulting potentially in the development of tumor-specific antibodies. mABs can also 
be used to therapeutically target cancer cells. For example, the mAB Trastuzumab 
recognizes the extracellular domain of the Her2/neu receptor, which belongs to the 
EGFR family and is overexpressed in 25% of breast cancers. Dimerization of the 
receptor leads to cell proliferation, cell survival and metastases19. By targeting these 
overexpressing tumors, a combination of Trastuzumab therapy with cytotoxic 
chemotherapy can promote survival in women with metastatic breast cancer compared 
to chemotherapy alone20.   
Another form of immunotherapy in use today involves checkpoint inhibitors. Cancer 
cells can evade immune destruction through expression of ligands that bind to 
checkpoint proteins on immune cells. Such proteins, like cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), programmed death-1 (PD-1) and lymphocyte antigen gene 3 
(LAG-3) regulate the immune system (generally inhibitory), and are important for self-
tolerance. Attachment of tumor ligands to checkpoint proteins can potentially dampen 
the anti-tumor immune response. Therefore, antibodies against checkpoint proteins or 
against tumor ligands which bind to checkpoints (PD-L1) have been developed to 
achieve long-lasting immunity21. In more detail, T cell activation occurs via two signals, 
where the first signal involves the interaction between antigens that are presented on 
MHC molecules of APCs and the T cell receptor. T cells then require a second, co-
stimulatory, signal that often involves the interaction of CD28 on T cells and 
CD80/CD86 on APCs. CTLA-4 is a CD28 homolog which rather transmits signals to 
inhibitory pathways in T cells after binding of CD80/CD86 22. Already in 1996, it was 
shown that blockade of CTLA-4 leads to the promotion of anti-tumor responses in 
mice23. In 2011, Ipilimumab was approved by the FDA as the first CTLA-4 checkpoint 
inhibitor that improved the overall survival of patients with metastatic melanoma24,25. 
PD-1 is also a CD28 homolog and binds to the ligands PD-L1 and PD-L2 that can be 
upregulated by IFN-γ26,27. Interaction between PD-1 and PD-L1/PD-L2 leads to 
immune suppression and is correlated with poor prognosis in some cancers like 
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melanoma and gastric cancer28-30. Pembrolizumab was the first antibody that was 
approved by FDA as a PD-1 inhibitor and is used for treatment in different cancer 
types31. Nivolumab is another PD-1 inhibitor that showed therapeutic responses of 
44% and progression-free survival rates of 6.9 months in patients with melanoma. 
Combination therapy of nivolumab and the CTLA-4 inhibitor ipilimumab enhanced 
response rates to 58% and progression-free survival to 11.5 months32,33.  In many 
cancer types, PD-L1 is constitutively expressed on tumor cells or the expression is 
induced by inflammatory signals34,35. Besides binding to PD-1, PD-L1 binds to 
CD80/CD89 which leads to dampening effects on T cell stimulation and anti-tumor 
activity36. The FDA has approved three different PD-L1 inhibitors at the moment: 
atezolizumab, durvalumab and avelumab37-39.  
Another promising cancer therapy uses chimeric antigen receptor (CAR) T cells 
(Fig.2). CARs are made by first harvesting T cells from patient blood. T cell receptors 
are genetically engineered in these cells ex vivo to improve the recognition of tumor-
associated antigens (TAAs) without prior presentation of these antigens through MHC 
molecules40-42. Thus, it is no longer possible for tumor cells to escape immune 
destruction through downregulation of MHCs43. Moreover, since CAR T cells are not 
dependent of MHC class I or II, CD8+ T cells as well as CD4+ T cells can be modified40. 
T cell receptors are engineered in different ways to become CARs. Besides viral 
transduction and use of transposons, T cell receptors are altered by CRISPR/Cas9 
vectors or through non-viral transfer methods. Currently, there is already the 4th 
generation of CARs which are able to simultaneously recognize a broad range of tumor 
antigens with high specificity and activate themselves due to signaling and co-
stimulatory domains in the intracellular part of the receptor44. After modification of T 
cell receptors, CAR T cells are expanded in culture with IL-2 and undergo extensive 
quality control before reinfusion into the cancer patient. During CAR T cell production 
in the laboratory, patients receive lympho-depleting chemotherapy to “make space” for 
the cells to be infused. Also, immune suppressive cells such as regulatory T cells 
(Tregs) and myeloid-derived suppressor cells (MDSCs) are depleted to improve the 
efficiency and persistence of CAR T cells45,46.  
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Once the cells are back in the patient and after the recognition of TAAs, CAR T cells 
kill tumor cells via secretion of perforins and granzymes and/or via the expression of 
Fas ligands to activate the Fas death signaling in malignant cells. The repertoire of 
ligands that can be recognized by CAR T cells is huge and diverse. However, 
presently, the most promising results of CAR T cell therapy are observed against B cell 
malignancies by treatment with anti-CD19 CARs47-49. 65% of the current 113 registered 
CAR T cell trials are targeting hematological malignancies50. However, CAR T cell 
therapy of solid tumors is more challenging due to a lack of tumor-specific antigens. 
Additionally, in hematological diseases, modified T cells have easy access to cancer 
cells and their tumor antigens. In contrast, migration into solid tumors requires 
attraction by chemokines, overcoming of tumor stroma and specific recognition of 
TAAs.  
 
Figure 2: Principle of CAR T-cell therapy (modified from 41). 
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Cytokines regulate the development and maturation of innate and adaptive immune 
cells and their communication. In cancer therapy, cytokines are used to activate or 
maintain patients’ immune responses against tumors. Mouse models first showed that 
interleukins (ILs) or interferons (IFNs) like IL-2, IL-12, IL-15, IL-21, GM-CSF 
(granulocyte-macrophage colony-stimulating factor) and IFN-α increase the number of 
effector immune cells and enhance their anti-tumor immunity51,52. Early on, IFN-α and 
high-dose IL-2 were approved for treatment of different human cancer types53. IFN-α 
is a type I IFN which upregulates the expression of MHC molecules on tumor cells54-
56. Moreover, IFN-α activates different types of immune cells including dendritic cells 
(DCs), macrophages, CD8+ T cells and NK cells57,58. Besides indirect effects of IFN-α 
on tumor cells through stimulation of anti-tumor immune cell activity, IFN-α directly 
interferes with proliferation and angiogenesis associated with malignant cells59-61. IL-2 
is used to stimulate T cell activation and expansion62; furthermore, IL-2 leads to 
secretion of cytokines and enhanced anti-tumor activities of NK cells, as well as B cell 
expansion and differentiation. However, efficacy of cytokine therapy with IL-2 is 
overshadowed by severe side effects. Besides life-threatening toxicities, IL-2 not only 
activates effector immune cells but also immune suppressive cells like Tregs and 
MDSCs63. Moreover, the expression of inhibitory checkpoint proteins is enhanced by 
IL-2 and the secretion of immune suppressive factors like IL-10 and TGF-β is 
stimulated. IL-15 shares many features with IL-2 including the activation of 
development, differentiation and anti-tumor activity of CD8+ T cells and NK cells64. 
However, it has some advantages in comparison to IL-2, since IL-15 is not as toxic and 
does not stimulate immune suppressive cells65. In Chapter 2.5 I will discuss IL-15 in 
more detail and the relevance for this thesis. Cytokines are not only used as in vivo 
adjuvants but also in vitro for stimulation and expansion of immune cells in adoptive 
cell therapy. Dendritic cells are stimulated with GM-CSF, IL-4, TNF-α, IL-6 and IL-1β, 
whereas IL-15 and IL-21 are the most prominent cytokines for activating and 
expanding T cells. Patients receive low-dose IL-2 after reinfusion of T cells to improve 
the survival of transferred cells leading to better clinical outcomes66.  
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2.2 Tumor immune surveillance and immunoediting 
The hypothesis that cancer development is monitored and controlled by immune cells 
was created decades ago. In the 20th century Frank MacFarlane Burnet and Lewis 
Thomas created the immune surveillance theory67. Different mouse models and also 
human studies confirmed this hypothesis and showed that the immune system, 
especially lymphocytes and their secreted cytokines, are able to recognize and 
eliminate primary tumors (reviewed in 68). However, doubts gradually arose about this 
hypothesis because of the development of cancer in immunocompetent mice with an 
intact immune system. Different further experiments showed the formation of tumors 
with reduced immunogenicity or the acquirement of mechanisms to evade or suppress 
the immune system. Therefore, the term “cancer immunoediting” was created including 
the host-protecting and tumor-sculpting processes of the immune system68. Dunn et 
al. divided the cancer immunoediting in three phases (three Es) which will be described 
in the following chapters: Elimination, Equilibrium and Escape (Fig.3).   
2.2.1 Elimination 
The elimination phase is known as the conventional cancer immune surveillance raised 
by Burnet and Thomas. In this phase, the immune system recognizes and eliminates 
transformed tumor cells before they become clinically apparent. For example, APCs 
like dendritic cells are activated by tumor-secreted danger signals (DAMPs, danger-
associated molecular patterns). In addition, T cells recognize tumor antigens with their 
T cell receptor provoking the induction of adaptive anti-tumor responses69,70. There are 
two different sorts of tumor antigens. A distinction is made between tumor-specific 
antigens (TSA) and tumor-associated antigens (TAA). TSAs are antigens that are only 
present on tumor cells but not on normal cells. In comparison, TAAs are expressed on 
tumor as well as on normal cells, however normally at lower levels on normal cells71,72. 
Besides APCs and T cells, NK cells and their receptors bind ligands (to be explained 
in a later chapter) expressed on tumor cell surfaces resulting in the release of 
immunomodulatory and pro-inflammatory cytokines which can kill tumor cells directly 
or again promote the development of tumor-specific adaptive immune responses73-75.  
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At that time, researchers thought that the immune system is able to completely destroy 
tumor cells. However, there are rare tumor cell variants surviving the elimination phase 
and entering the next phase of the immunoediting process, the “equilibrium”.  
2.2.2 Equilibrium 
Some tumor cells which were not recognized and destroyed by immune cells in the 
aforementioned elimination phase go into dormancy76. These cells stop their 
proliferation, development and activity for periods of time up to decades in length. In 
this equilibrium phase tumor cells adapt to constant selection pressure of adaptive 
immune cells, especially by T cells or via genetic instability. T cells even sculpt the 
immunogenicity of the tumor, as was confirmed in different transplant models. For 
instance, tumors from mice with immunodeficiency were more immunogenic than 
tumors from immunocompetent mice, presumably because tumor cells with stimulatory 
antigens were not as likely to be eliminated. Transplantation of these tumors into 
wildtype mice showed a higher elimination rate of tumors raised in an immunodeficient 
background76. Only highly immunogenic cells were eliminated and non-immunogenic 
cells could grow77. Moreover, deficiencies in IL-12 and IFNγ signaling pathways lead 
to progressive tumor growth when transplanted into wildtype mice. This work served 
to demonstrate the role of adaptive immune components in changing (sculpting) tumor 
immunogenicity78. 
2.2.3 Escape 
In the last phase of the immunoediting process, called the “escape” phase, edited 
tumor cells with low immunogenicity start growing again and appear as visible tumors. 
They are resistant to detection and elimination by the immune system. The entry into 
this phase can be caused by different events. Tumor cells are able to change the 
expression of tumor antigens and ligands (e.g. MHC components)79. Downregulation 
allows tumor cells to be invisible to immune cells and further tumor progression can 
occur80,81. Moreover, tumor cells producing immunosuppressive cytokines like tumor 
growth factor β (TGF-β), vascular endothelial growth factor (VEGF), indoleamine 2,3-
dioxygenase (IDO) or IL-10 can favor the microenvironment towards tumor growth82,83.  
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Recruitment of Tregs and MDSCs can also inhibit anti-tumor responses as another 
escape mechanism for tumor cells to evade immune surveillance. 
 
Figure 3: Three E´s of cancer immunoediting: Elimination, Equilibrium and Escape (modified from68,84). 
Abbreviations: NKR= natural killer cell receptor, DAMPs= danger-associated molecular patterns, NK cell= 
natural killer cell, DC= dendritic cell, NKT= natural killer T cell, MHC= major histocompatibility complex, IL= 
interleukin, TGF= transforming growth factor, IDO= Indolamin-2,3-Dioxygenase, VEGF= Vascular 
Endothelial Growth Factor, PD-L1= programmed cell death ligand 1, Tregs= regulatory T cells, MDSCs= 
myeloid-derived suppressor cells. 
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2.3 Natural Killer (NK) cells 
2.3.1 General characteristics and functions  
The innate immune system includes physical epithelial barriers, phagocytic leukocytes, 
dendritic cells and natural killer (NK) cells. The latter NK cells are large granulocytes 
which are widely distributed in minor fractions (2-10% in mouse, 2-18% in human) in 
lymphoid and non-lymphoid tissues. NK cells are capable to recognize and kill 
pathogen-infected or neoplastic cells without prior sensitization85. There are different 
ways how NK cells can act:   
Firstly, NK cells secrete two main cytotoxic proteins.  Effector NK cells release perforin 
resulting in disruption of cell membranes followed by secretion of granzymes. 
Granzymes are serine proteases that can pass cavernous cell membranes of target 
cells and induce apoptosis (Fig 4; 1)86,87. Different studies using perforin-deficient mice 
show the importance of this protein in NK cell cytotoxicity and tumor immune 
surveillance, whereas the role for granzymes is less well described88,89.   
Secondly, NK cells activate the Fas death receptor pathway by expressing FasL and 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on NK cell surfaces 
leading to programmed cell death90,91 (Fig. 4; 2). Furthermore, secretion of IFN-γ by 
NK cells induces the expression of death receptors on target cells92. However, 
signaling through IFN-γ is slower than the perforin/granzyme pathway, occurring only 
after several hours.  
Thirdly, for example, after treatment of patients with a monoclonal antibody therapy, 
NK cells recognize antibody-coated tumor cells with their Fc receptors (e.g. CD16). 
These receptors cross-link and activate NK cells and induce ADCC (Fig.4; 3).    
After NK cell activation, secretion of cytokines like IFN-γ, TNF and GM-CSF leads to 
activation of further innate immune cells such as DCs, macrophages and neutrophils. 
Moreover, NK cells can activate the adaptive arm of the immune system, especially T 
cells93 (Fig.4; 4). Different chemokines like IFN-γ, GM-CSF and TNF produced by NK 
cells attract the aforementioned effector cells to sites of inflammation. Especially IFN-
γ can initiate the upregulation of MHC class I and II on other immune cells resulting in 
stimulation of antigen presentation and orchestration of immune cell interactions85. 
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Tumor cell proliferation and growth can be dampened with the antiangiogenic 
interferon gamma-induced protein 10 (IP-10), also induced by IFN-γ94. 
 
Figure 4: Different mechanisms of NK cell killing of tumor cells. 1. Secretion of perforin and granzymes; 2. 
Expression of FasL and TRAIL to initiate Fas death pathway; 3. Antibody-dependent cell cytotoxicity; 4. 
Cytokine secretion for activation of other innate and adaptive immune cells. Abbreviations: IFN= interferon, 
TRAIL= Tumor Necrosis Factor Related Apoptosis Inducing Ligand, TNF= tumor necrosis factor, GM-CSF= 
Granulocyte-macrophage colony-stimulating factor, DC= dendritic cell, ΜΦ= macrophages.  
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2.3.2 Inhibitory and activating NK cell receptors 
A wide range of inhibitory and activating cell surface receptors regulates NK cell 
activity. These receptors are genetically encoded in comparison to ones of B and T 
cells which are made by somatic recombination85. Expression of different combinations 
of receptors leads to heterogeneity within the NK cell population and offers the 
opportunity to respond to a diversity of stimuli.  
Inhibitory receptors such as killer immunoglobulin-like receptors (KIRs, human) and 
C-type lectin-like receptors (Ly49, mouse) mainly bind to MHC class I molecules, which 
are human leukocyte antigen (HLA) class I molecules in humans95,96. Another group 
of inhibitory receptors such as CD94/NKG2A receptors recognize non-classical MHC 
class I molecules (HLA-E in human; Qa-1 in mouse)97,98. The receptors have 
cytoplasmic immune receptor tyrosine-based inhibitory motifs (ITIMs), which are 
phosphorylated after binding of these ligands. The phosphorylation results in 
recruitment and activation of tyrosine phosphatases SHP-1 and SHP-2, leading to 
downstream signaling and inhibition of NK cells99,100. Absence of MHC class I 
molecules on target cells (“missing-self”) and/or stimulation of activating receptors 
activates NK cell cytotoxicity. Therefore, healthy cells that express high levels of MHC 
class I molecules are spared from NK cell activity. Killer cell lectin-like receptor G1 
(KLRG1) binds cadherins and acts through an ITIM, like the receptors mentioned 
above101,102. In Table 1, inhibitory receptors of human and mouse NK cells with their 
corresponding ligands are listed.  
Additionally to inhibitory receptors, NK cells also express a wide range of activating 
receptors. The signaling occurs through immune-receptor tyrosine-based activating 
motifs (ITAMs). Tyrosine residues are phosphorylated after binding of a ligand followed 
by recruitment of the kinases. Afterwards, downstream signaling leads to degranulation 
of cytokines and chemokines. However, stimulation of more than one activating 
receptors is required to activate NK cells103, and strong stimuli are needed to overcome 
inhibitory signals. Besides signaling through activating KIRs and Ly49 receptors, 
stimulation of NKG2D leads to proliferation, cytotoxicity and cytokine production by NK 
cells104.  
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Natural cytotoxicity receptors (NCRs), e.g. NKp30, NKp44 or NKp46 bind a wide range 
of bacterial-, virus- and parasite-originating ligands and are also involved in NK cell 
cytotoxicity against tumor cells105-107. CD16 recognizes specific antigens on tumor cells 
and induce tumor cell death by ADCC108.  In Table 2, activating receptors of human 
and mouse NK cells with their corresponding ligands are listed. 
Table 1: Inhibitory receptors of human and mouse NK cells 
Inhibitory receptors  Receptor Ligand  
Human  KIR HLA-A/B/C 
 CD94/NKG2A HLA-E 
 KLRG1 Cadherin E/N/R 
Mouse  Ly49A/C/I/P MHC class I 
 CD94/NKG2A Qa-1 
 KLRG1 Cadherin E/N/R 
 
Table 2: Activating receptors of human and mouse NK cells 
Activating receptors  Receptor Ligand  
Human KIR HLA-A/B/C/G 
 NKG2C/E HLA-E 
 NKG2D MICA/MICB/ULBP 
 NKp30, NKp40, NKp46 (NCRs) Viral-, bacterial, parasite-, 
cellular-  ligands 
 CD16 -  
Mouse  Ly49D/H MHC class I 
 NKG2C/E Qa-1 
 NKG2D H-60/Rae-1/Mult1 
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2.3.3 Human NK cell subpopulations 
Human lymphocytes consist of 2-18% NK cells that are distinguishable from T cells 
due to the absence of CD3 expression. They can be divided into two subpopulations 
identified by the cell surface marker CD16 and CD56 109. On the one hand, there are 
CD16brightCD56dim NK cells that are highly cytotoxic immune cells with poor cytokine 
production110,111. They constitute 90-95% of NK cells and are present in blood and at 
sites of inflammation112. The high expression of CD16 binding to immunoglobulins 
leads to killing of target cells through ADCC. On the other hand, 
CD16dim/negativeCD56bright NK cells predominantly located in lymph nodes are less 
cytotoxic but are potent producers of cytokines like IFN-γ, TNFβ, IL-10, IL-13 and GM-
CSF after obtaining different activation signals109. NK cells respond to cytokines like 
IL-1, IL-2, IL-12, IL-15 or IL-18 released by other immune cells such as APCs or 
through signals recognized by their activating receptors CD16 and NKG2D109,113.   
2.3.4 Mouse NK cell subpopulations 
Mouse NK cells do not express CD56, and are rather divided by their expression of 
surface markers CD11b and CD27 representing their differentiation status114. They 
develop from CD11bnegCD27high immature (iNK), over CD11bposCD27high mature NK 
cells to CD11bposCD27low terminally-differentiated NK cells115. CD27high are 
comparable to CD56bright human NK cells also present in lymph nodes with a high 
capacity to produce cytokines like IFN-γ. They have the ability to kill tumor cells which 
express MHC I, which is consistent with the lower levels of inhibitory receptors for MHC 
I on CD27high  NK cells110. Terminally-differentiated CD27low NK cells show low 
cytotoxicity and reduced production of cytokines. Concerning proliferation there are 
also differences between subsets. Immature and CD27high NK cells have high 
proliferation capacity in comparison to CD27low cells with a limited ability to divide. 
Mature NK cells also express KLRG1 which is an inhibitory receptor and marker of 
terminal differentiation116. NK cell development is dependent of different cytokines 
recognized by receptors containing a common gamma (γc) chain. Signaling through γc 
is required for their differentiation, homeostasis and function. This subunit is part of the 
recognition complex for cytokines such as IL-2, IL-4, IL7, IL-9, IL-15 and IL-21117. IL-
12 and Type I IFNs activate NK cells leading to antitumor activity118.  
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2.3.5 NK cells in cancer and metastasis 
As described in chapters above and shown in many in vitro and in vivo studies, NK 
cells play an important role in tumor immune surveillance by spontaneous killing of 
tumors without prior sensitization119,120. In the course of immune evasion, malignant 
cells downregulate their expression of MHC class I to escape recognition by receptors 
of CD8+ T cells. Consequently, NK cells are able to detect these tumor cells (“missing 
self”) which results in NK cell proliferation and cytotoxicity including cytokine production 
and release of lytic granules121,122. Furthermore, expression of stress-induced 
molecules (MICA, MICB and UL-16) on tumor cells leads to stimulation of activating 
NKG2D receptor122,123. Studies showed that patients with high levels of peripheral 
blood NK cells have a longer metastasis-free survival85. However, mice with 
deficiencies in NK cell cytotoxicity components like perforin and IFN-γ show an 
increased incidence of tumors75,124. Moreover, perforin is important in controlling the 
formation of metastasis125,126.  
2.3.6 NK cells in immunotherapies  
NK cells have been used in different therapy options against cancer. Autologous NK 
cell therapy includes extraction of NK cells from patients, followed by in vitro 
manipulation to expand them and increase their cytotoxicity before reinfusing into 
patients where they are then better able to seek out and destroy tumor cells127,128. 
However, this therapy has limitations, such as through inhibition of NK cells by tumor 
cell expression of self-HLA molecules129. Hence, allogeneic NK cell therapy is 
performed with transplantation of allogeneic hematopoietic stem cells or infusion of 
mature allogeneic NK cells. Administration of monoclonal antibodies is another method 
to induce ADCC by NK cells. These antibodies bind to tumor cells that are then 
recognized by the activating receptor CD16 on NK cells130,131. Besides use of different 
cytokines to expand and activate immune cells, modified NK cells called chimeric 
antigen receptor (CAR) NK cells have been utilized. These CAR NK cells are 
genetically engineered for more efficient and specific binding to tumor antigensf132-134.  
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2.4 CD8+ T lymphocytes  
2.4.1 General characteristics and functions 
CD8+ T cells are cytotoxic T lymphocytes (CTLs) that are generated in the thymus and 
belong to the adaptive arm of the immune system. Their major role is the clearance of 
intracellular pathogens and tumors. After recognition of foreign MHC class I antigens 
presented by APCs, CD8+ T cells perform effector functions comparable with those of 
NK cells. CD8+ T cells release perforin and granzymes to kill malignant cells. Secretion 
of IFN-γ and TNF-α strengthens their immune response and activates other cells of the 
innate and adaptive immune system135. Like NK cells, CD8+ T cells express FasL on 
the cell surface binding to the Fas receptor on target cells. After activation of the 
caspase cascade, targets cells to go into apoptosis. 
2.4.2 Activation of CD8+ T cells 
Naïve CD8+ T cells migrate from the thymus to secondary lymphoid organs, like lymph 
nodes and spleen, where they are activated to mediate immune responses136.  The 
activation of CD8+ T cells requires two different signals: Signal 1 is the binding of a 
MHC protein by specific T cell receptors (TCRs) which is provided by APCs like 
dendritic cells137. Importantly, CD8+ T cells recognize the main structure of MHC class 
I molecules, rather than the specific peptide in the MHC molecule cleft which is 
recognized by CD4 helper T cells. Signal 2 is mediated via stimulation through a co-
receptor interaction with e.g.  CD28 receptor on the T cell surface and B7 proteins 
(CD80/CD86) on APCs. Signaling through CD28 enhances signal 1 and is necessary 
for proliferation and activation of effector functions. Absence of signal 2 leads to 
apoptosis of T cells and represents one mechanism of self-tolerance. After binding of 
MHC and CD80/CD86 by T cells, downstream signaling leads to IL-2 production and 
stimulation of CD8+ cell proliferation in an autocrine and paracrine feedback loop. 
Effector cells produce cytokines like IFN-γ and TNF-α as well as perforin and 
granzymes. After performing their effector functions, 95% of the CD8+ T cells die and 
only a small fraction of memory CD8+ T cells persist. With the presence of specific 
cytokines like IL-15 these memory cells can survive in the host138. 
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2.4.3 Human CD8+ T cell subsets 
Human CD8+ T cell development occurs in the following order with increasing cell 
differentiation and effector functions and decreasing memory function and proliferation: 
naïve T cells (TN), stem cell memory cells (TSCM), T central memory cells (TCM), T 
effector memory cells (TEM) and T effector cells (Teff)42. Human CD8+ T memory and 
effector cells can be divided by the markers CD27 and CD45RA. Naïve CD8+ T cells 
express both markers in comparison to memory cells only expressing CD27 and 
effector cells only expressing CD45RA139. CCR7 is another marker distinguishing 
CD8+ T subsets. Memory cells express this gene in contrast to effector cells which do 
not show CCR7 expression140. CCR7 is a chemokine receptor which is responsible for 
T cell trafficking and homing within secondary lymphoid organs141.  
2.4.4 Mouse CD8+ T cell subsets 
Mouse CD8+ T cells differentiation is similar to that of human CD8+ T cells. Naïve T 
cells differentiate to effector, TEM and finally to TCM cells142. CD8+ T cell subsets in mice 
can be identified by the expression markers CD44 and CD62L. They differentiate from 
naïve CD44low CD62Lpos T cells (TN) to CD44high cells that can be further distinguish 
into CD62Lneg effector T cells (Teff) and CD62Lpos central memory T cells (TCM). 
These two effector cell subsets differ in location and effector functions (Fig. 5). Teff 
cells are found in inflamed peripheral tissue with high effector functions like production 
of high amounts of perforin, IL-4, IL-5 and IFN-γ after antigen stimulation143. On the 
contrary, TCM cells are in secondary lymphoid organs displaying less or no effector 
functions. However, TCM cells secrete IL-2 quickly after stimulation resulting in a 
feedback loop leading to their proliferation and differentiation into Teff cells with IFN-γ 
secretion140. TCM cells can be activated by antigen stimulation as well as by response 
to different cytokines. For example, in vivo mouse studies show proliferation of T cells 
after stimulation with IL-7 and IL-15 144,145. 
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Figure 5: Mouse CD8+ T cell subsets with different locations and effector functions: effector CD8+ T cells 
(Teff); central memory CD8+ T cells (TCM) 
2.4.5 CD8+ T cells in cancer and metastasis 
T cells entering tumors are called tumor-infiltrating lymphocytes (TILs) and are 
considered as a positive prognostic marker in many different solid tumors146-148. CD8+ 
T cells kill target cells in different ways comparable to the capabilities of NK cells. 
In vivo studies show earlier tumor onset in mice lacking lymphocytes or the IFN-γ 
receptor after injection of methylcholanthrene (MCA)-induced sarcoma in comparison 
to wildtype mice. Similar results are observed in mice developing spontaneous 
epithelial tumors124. However, during tumor progression CD8+ T cells can become 
exhausted and tumor cells evade tumor immune surveillance through different 
mechanisms149. CD8+ T cell-secreted IFN-γ enhances expression of PD-L1 on cancer 
cells which binds to PD-1 on T cells leading to suppression of their activity. Moreover, 
Tregs in the tumor microenvironment induce CTLA-4 expression on T cells by releasing 
adenosines, also resulting in immunosuppression after binding of the ligand 
CD80/CD86 on tumor cells150. Cancer cells stimulate MDSCs to produce TGF-β 
enhancing the activity of immunosuppressive Tregs151.  
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Besides adenosines, many other immunosuppressive compounds are released by 
cancer cells to escape killing by CD8+ T cells. Therefore, CD8+ T cells can either 
destroy or spare cancer cells, depending on the exact circumstances in the tumor 
microenvironment.  
2.4.6 CD8+ T cells in cancer immunotherapy 
To avoid peripheral tolerance of tumor cells by immune cells, immune-based therapy 
has become a standard or experimental procedure for treatment of many 
cancers152,153. The aim of such therapies is the reactivation and expansion of tumor-
specific cytotoxic T cells resulting in more targeted killing of tumor cells.  
A very promising therapy is the use of monoclonal antibodies against checkpoint 
proteins on T cells.  Many solid and hematopoietic tumors are treated with antibodies 
against CTLA-4 and/or PD-1/PD-L1 which prevent T cell inhibition by tumor cells and 
boost the activation of effector T cells to kill these malignant cells154. Earlier in this 
review, the need for co-stimulation (signal 2) of T cells to activate or inhibit their activity 
was covered. Tumor cells can evade T cells by expressing inhibitory molecules, so the 
antibodies mentioned above serve to block these inhibitory ligands/receptors. 
Currently, there are different clinical studies evaluating the efficiency of checkpoint 
inhibitors. However, only a small portion of patients show benefits from these therapies 
because of the development of resistances against the inhibitors155. Combination 
therapies with e.g. chemotherapy or CAR T cell therapy show higher response rates 
than monotherapies156.  
Another approach is by CAR T cell therapy. In CAR T cell therapy, T cells from patients 
are isolated from blood and genetically engineered in a biotechnology laboratory to 
express a chimeric antigen receptor that specifically recognizes tumor antigens. The 
receptor consists of an extracellular domain binding to tumor cells and intracellular co-
stimulatory and signaling domains responsible for proliferation and activation of 
effector functions of CAR T cells after binding of tumor antigens157. By changing the 
combinations of co-stimulatory and signaling domains the anti-tumor activity of these 
CAR T cells is improved significantly over time158.  
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Presently, only CD19-specific CAR T cell therapies are approved by the FDA. 
However, the advantages of this therapy in comparison to the aforementioned use of 
monoclonal antibodies are a high response rate and small numbers or lack of minimal 
residual cancer. CAR T cells also express checkpoint proteins after contact with tumor 
cells, giving them long term activity. Therefore, combination therapies with checkpoint 
inhibitors are performed to improve the cytotoxicity of CAR T cells and their secretion 
of IFN-γ159. Moreover, CAR T cell efficiency is enhanced by use of interleukins like IL-
2, IL-4, IL-7, IL-12, IL-15 and IL-21.  
2.5 Interleukin 15 (IL-15) 
Immunotherapy takes advantage of the immune system to kill malignant cells without 
affecting healthy tissue. However, tumor cells can evade immune surveillance by 
interfering with the development and function of anti-tumor responses. Cytokine 
therapy was one of the earliest approaches to stimulate immune responses and 
develop long-lived tumor immunity. In early studies decades ago, treatment with IL-2 
sometimes caused impressive tumor regression responses. However, only few 
patients responded to this therapy and there were very severe side effects160,161. 
Interleukin  15 (IL-15), has more recently been used in cancer immunotherapy by the 
US National Cancer Institute and deserves further introduction especially with regard 
to this thesis162.  
2.5.1 Characteristics and signaling pathways 
IL-15 is a four-α-helix protein belonging to the same family as IL-2. IL-15 can be 
produced by APCs. For example, dendritic cells produce IL-15 in the endoplasmic 
reticulum after their activation. Bound to an IL-15 receptor alpha subunit (IL-15Rα), IL-
15 is transferred through the cytoplasm to the cell surface of APCs to be presented to 
effector immune cells163. A receptor complex on responding effector cells consisting of 
an IL-2/IL-15 receptor β (IL-15Rβ; CD122) subunit and a common gamma chain (γc; 
CD132) receptor subunit bind to IL-15 with high affinity (Fig. 6). This binding results in 
the activation of Janus kinases followed by initiation of the STAT5 pathway164. 
Moreover, IL-15 additionally stimulates the RAS-MAPK and PI3K-AKT pathway in 
effector immune cells165. Downstream signaling leads to proliferation, activation, 
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migration and decreased apoptosis of immune cells carrying the IL15 receptor complex 
like CD8+ T and NK cells64,144,166,167. IL-15 in complex with the α subunit is also found 
in soluble form after cleavage from cell surfaces upon inflammatory signals168. The 
binding of IL-15 to IL-15Rα is transient and short-lived but it prolongs the half-life of IL-
15 and enhances the affinity to the other subunits169.  
 
Figure 6: IL-15 receptor complex. IL-15 in complex with the IL-15α subunit is presented by APCs to the IL-
2/IL-15β and IL-15γ subunit expressed on effector immune cells (modified from 170). 
2.5.2 Pro and contra of IL-15 immunotherapy   
IL-15 was first tested in mice and non-human primates with enhancing effects on 
proliferation, differentiation and survival of CD8+ T cells and NK cells64,166. Additionally, 
in comparison to IL-2, treatment with IL-15 does not stimulate immunosuppressive 
Tregs. Systemic treatment with this cytokine shows tumor regression and lower 
numbers of metastases in murine tumor models171-173. Moreover, mice treated with IL-
15 show more long-lasting anti-tumor effects of immune cells than mice treated with 
IL-2. Besides transient toxicities, animals respond well to treatment with IL-15 and 
therefore the cytokine was first given intravenously in adults with metastatic melanoma 
and renal cell cancer in an in-human phase I clinical trial. In this trial, Conlon et al. first 
observed a significant decrease in peripheral blood NK cells and memory CD8+ T cells 
shortly after IL-15 administration. After 4 hours, levels of NK cells were normalized 
again for 2-3 days, followed by a 10-fold increase in NK cell numbers which declined 
again over the following 6 weeks174. CD8+, but not CD4+, T cells showed a similar 
expansion due to enhanced proliferation after IL-15 administration. Reduction of lung 
metastases in melanoma patients was observed, however, treatment with higher 
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doses of IL-15 led to toxicities and elevated levels of pro-inflammatory cytokines. It 
must also be taken into consideration that IL-15 has a short half-life, resulting in the 
need for long-term administration to patients thereby enhancing the clinical side 
effects.  
2.5.3 Improvements of IL-15 agents 
Improvements in quality and efficiency of IL-15 have been made. Like mentioned 
before, IL-15 in complex with the IL-15α subunit is more stable and enhances the 
affinity to the other receptor subunits. One strategy has been the generation of a 
complex consisting of the recombinant protein IL-15 (rIL-15), murine IL-15Rα and the 
Fc portion of a human IgG1 antibody (IL-15/IL-15Rα-Fc). This complex prolongs the 
half-life of IL-15 from 1 hour to 20 hours175. Moreover, the complex shows more potent 
effects on immune cells with resulting improvement in anti-tumor immunity in vivo 
compared to IL-15 alone169,176,177. Different versions of such complexes have been 
created by different companies in the last years and are being tested.  
2.5.4 IL-15 combination therapies 
In addition to treatment with single IL-15 agents, the cytokine/cytokine complexes are 
used in combination with other therapies. For example, IL-15 is combined with 
chemotherapy to enhance anti-tumor responses where, for example, a reduction in 
tumor burden and longer survival of mice was observed178,179. The simultaneous 
administration of IL-15 complexes and checkpoint blocking antibodies against PD-1 
and CTLA-4 enhances the activity of T cells in different tumor mouse models. Besides 
longer survival of the animals, tumor growth was reduced after treatment with the 
combination therapy180,181. The use of CD40 antibodies combined with IL-15 in mice 
results in activation of dendritic cells with following IL-15Rα expression182. Then, the 
effect of IL-15 is amplified and the anti-tumor activity of tumor-specific CD8+ T cells 
and NK cells is enhanced183. After successful treatment of animals with IL-15 
combination therapies, the agents are currently being tested in clinical trials to test the 
safety of IL-15184. Additionally, the most effective dose of IL-15 needs to be found to 
get optimal anti-cancer therapeutic treatments. 
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2.6 Spontaneous melanoma mouse model – Grm1 
We have used a spontaneous melanoma mouse model generated by Pollock and 
colleagues in 2003 to study the role of NK and CD8+ T cells185. This research group 
utilized a mouse mutant, TG3, carrying multiple tandem insertions of the transgene into 
intron 3 of the metabotropic glutamate receptor 1 (Grm1). These insertions resulted in 
deletion of 70kb of the intronic sequence leading to overexpression of Grm1. To only 
induce transgenic expression in melanocytes they created a further mouse strain in 
which the expression of Grm1 is driven by the dopachrome tautomerase (Dct) 
promotor. Dopachrome is an intermediate product in the biosynthesis of melanin. 
These mice, called Tg(Grm1)EPv, spontaneously develop melanomas at hairless skin 
regions (e.g. tail, ears) with 100% penetrance185. Metabotropic glutamate receptor 1 is 
a G-protein-coupled receptor binding L-glutamate followed by activation of 
phospholipase C. Subsequent formation of second messengers (IP3 and DAG) results 
in downstream signaling of pathways involving MAPK and PI3K/AKT, already known 
to participate in melanomagenesis186,187. In MAPK signaling, the G protein RAS 
activates RAF followed by activation of MEK and ERK leading to direct activation of 
transcription factors in the nucleus that regulate survival and proliferation of cells. 
Moreover, activation of ERK can stimulate the NF-κB pathway to also regulate survival, 
invasiveness and angiogenesis. The PI3K/AKT pathway activates on the one hand the 
mammalian target of rapamycin (mTOR) and on the other hand the NF-κB pathway 
resulting in cell proliferation and survival as well as cancer progression and 
angiogenesis186. Thus, overexpression of Grm1 leads to increased levels of the ligand 
glutamate in the extracellular space. This results in aberrant activation of the receptor 
in a paracrine feedback loop and constitutively activated downstream signaling188. 
Besides participation of the metabotropic glutamate receptor 1 in melanomagenesis, 
mutations in different other human cancer types have been observed, such as breast 
cancer189-191, prostate cancer192 and renal cell carcinoma193.  
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2.7 BalbNeuT breast cancer model 
In the spontaneous melanoma model (Grm1) we are able to study immune cell 
changes at specific time points during tumor progression and metastasis formation. To 
further analyze the role of immunoediting processes in metastatic progression we use 
another mouse model, called the BalbNeuT breast cancer model194. BalbNeuT mice 
have a gene, called neu (Erbb2), which is regulated by the mammary gland-specific 
MMTV promotor195. During puberty the neu gene is activated by this promotor resulting 
in development of independent carcinomas evolving to invasive tumors of the breast 
tissues. By transplantation of mammary glands of BalbNeuT mice into wt Balb/c mice 
we can change hosts and consequently the immune system (Fig.7) between primary 
and metastasis development. Thus, we can analyze the role of immunoediting 
processes after primary tumor establishment. By transplantation of mammary glands 
of BalbNeuT mice into immunodeficient mice lacking either NK (Balb/c IL2Rγ-/-) or B 
and T cells (Balb/c Rag2-/-) specific roles of each immune cell population in tumor 
immune surveillance could be investigated closer. Besides the monitoring of tumor 
growth and metastasis formation per se, we could check immune cell subsets in the 
presence or absence of primary tumors/metastasis.  
 
Figure 7: Schematic illustration of the BalbNeuT model 
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2.8 Glutamate – ligand of the Grm1 receptor 
Glutamate (Glu) is known as a non-essential amino acid serving as the major excitatory 
neurotransmitter in the central and peripheral nervous system (CNS). Extracellular 
glutamate levels at physiological concentrations (1-10µM) are normally associated with 
processes like learning, memory and behavior196. Glutamate can modulate 
proliferation, differentiation, migration and survival of progenitor cells and immature 
neurons. However, aberrant Glu signaling can activate respective receptors leading to 
excitotoxicity, a process describing the excessive Glu release or persistence of Glu in 
the synaptic cleft. Massive calcium influx via ionotropic glutamate receptor channels 
can lead to apoptosis of neuronal cells followed by neurodegenerative diseases like 
Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease and multiple 
sclerosis197-200.  
Glutamate acts via different glutamate receptors. Besides the already described Grm1 
receptor there are other metabotropic receptors (mGluRs) consisting of eight subtypes, 
mGluR1-mGluR8. These G-protein-coupled receptors are partitioned into three groups 
based on their sequence homology and intracellular signal transduction mechanisms. 
mGluR1 and mGluR5 belong to group I and are coupled to phospholipase C. Group II 
consists of mGluR2 and mGluR3, Group III of mGluR4, mGluR6, mGluR7 and mGluR8 
whereas all are negatively coupled to adenylate cyclase201. Moreover, there are 
ionotropic receptors (iGluR) subdivided into N-methyl-D-aspartate receptors 
(NMDAR), 2-amino-3-hydroxy-5-methyl-oxazole-4-propionic acid (AMPA) receptors 
and kainic ammonia acid (KA) receptors202. These are ligand-gated ion channels 
activated after binding of the ligand.   
Glutamate signaling is not only observed in the CNS, but also in peripheral tissues. In 
vivo studies with radiolabeled glutamate receptor binding agents have shown the 
expression of particular components of the glutamatergic system outside the CNS like 
in heart, kidney, intestine, lungs, muscles, liver, ovary, testis, bone and pancreas203-
205. Glutamate is also present in blood and there is some evidence that glutamate can 
have different effects on immune cells, especially on T cells depending on the 
concentration206.  
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Moreover, calcium influx can be promoted by low physiological concentrations207. 
However, at higher concentrations above 10-4M Glu can have inhibitory effects on T 
cells206,208,209. 
During the experiments with the Grm1 model we also analyzed immune cells subsets 
of Grm1 Tbet-/- (Tbx-/-) mice.  Tbet is a key transcription factor involved in maturation 
and differentiation of naïve T cells in effector and memory T cells. We observed that 
Grm1 Tbet-/- mice showed a reduction in effector T cells and especially in central 
memory T cells in comparison to B6 wt mice or B6 Tbet-/- mice (Fig.8).  
 
 
Figure 8: Comparison of CD8 T cell subsets in B6 wt, B6 Tbet-/- and Grm1 Tbet-/- mice. Grm1 Tbet-/- mice 
show reduction of the central memory T cell subpopulation 
Moreover, recently, Shah et al. demonstrated elevated glutamate concentrations in 
mice with aberrant Grm1 expression (~50mM)210. Namkoong and colleagues also 
showed increased glutamate release by melanoma cells with constitutively activated 
Grm1 receptors in vitro188.  
On the basis of our observation and the finding of Shah et al., we became interested 
in studying the role of glutamate on different immune cells subsets in the context of 
spontaneous melanoma development in mice. We therefore investigated possible 
effects of glutamate on activation of T cells and their influence on anti-tumor activity.  
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2.9 Background and aim of this project 
In 2014, Malaisé and other of our colleagues investigated the role of NK cells in the 
anti-tumor response to metastatic colorectal carcinoma (CRC) 211. They used Balb/c 
Tbet-/- mice to evaluate the role of different subsets of NK cells. The transcription factor 
Tbet is important for maturation and development of NK cells. Interestingly, in Tbet-/- 
mice, terminally differentiated NK cells (CD27low mature NK) do not develop. Therefore, 
Malaisé and co-workers hypothesized that the lack of this important subset can lead to 
pulmonary CRC metastases after adoptive transfer of CT26 CRC cells in Tbet-/- mice. 
They could show that intravenous injection (i.v.) of luciferase-labeled CT26 CRC cells 
(CT26-luc) leads to lung metastases within 8-11 days. After adoptive transfer of CT26 
CRC cells in combination with sorted wt CD27low/high NK cells, reduced pulmonary 
metastasis formation was observed.   
Since IL-15 is known to expand NK cells with high cytotoxic effector functions in vivo212, 
Malaisé et al. treated Tbet-/- mice with IL-15 and injected CT26-luc cells 2 days later. 
They observed no metastasis formation in lungs after single dose treatment with this 
cytokine. Further analysis of NK cells revealed that IL-15 activated the transcription 
factor Eomes compensating for the lack of Tbet and enabled the formation of effector 
NK cells. With this study, it could be shown that distinct NK cell subsets are responsible 
for preventing pulmonary CRC metastases in mice. However, it must be noted that this 
mouse model does not reflect real metastasis formation, as intravenous injection of 
tumor cells is actually a “seeding” model. After intravenous infusion, tumor cells first 
become trapped in lungs, where they can form tumors. Therefore, in this PhD thesis 
work I preferentially used the spontaneous melanoma mouse model, described in 
section 2.6, to study the more natural role of innate and adaptive immune cell 
development of lung and liver metastasis during spontaneous (natural) melanoma 
progression. I also have used IL-15 as a treatment to boost immune cell activation and 
activity. The goal was to confirm the findings of Malaisé et al. and gain deeper insight 
into tumor immune surveillance. Furthermore, due to the potential activity of glutamate 
on T cells critical for melanoma metastasis formation in the melanoma transgenic Grm1 
mouse model, I have studied the in vitro effects of glutamate on T cell populations, and 
have correlated these results with in vivo immune monitoring in Grm1 mice. 
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2.10 Hypotheses  
We hypothesize that NK cells and CD8+ T cells play a role in tumor immune 
surveillance in mice during the natural evolution process of neoplasm development, 
and their maturation and effector functions are inhibited over time as the cancer 
becomes increasingly malignant and metastatic.  
2.10.1 Spontaneous melanoma mouse model – Grm1 
We used the Grm1 melanoma mouse model to study the role of immune cells in tumor 
immune surveillance in the context of spontaneous tumor development. In previous 
work with a tumor-seeding model, we could observe that IL-15 activates effector 
immune cells in vivo that are able to kill tumor cells and prevent metastasis formation. 
We wanted to confirm these findings by treating Grm1 mice with IL-15. We 
hypothesized that repetitive IL-15 injections boost the immune system, which 
subsequently leads to slower tumor growth and smaller numbers of lung and liver 
metastases.   
2.10.2 BalbNeuT breast cancer model 
The BalbNeuT breast cancer model was used to study the role of immunoediting 
processes. After transplantation of mammary glands of BalbNeuT mice into Balb/c wt 
mice, we first expect tumor formation within several weeks. We think that malignant 
cells can adapt to the new microenvironment and form breast tumors. With 
development of tumors, we predict a change in the distribution of NK cell and CD8+ T 
cell subsets more towards effector immune cells. Moreover, the activity of these cells 
should also be changed in the presence of tumor cells. After removal of the primary 
tumor we expect that immune cell subsets normalize again and are reactivated during 
metastasis formation a few weeks after curative surgery of the primary tumor. Again, 
we hypothesize that the activity of NK cell and CD8+ T cell subsets is dependent on 
the absence or presence of primary or secondary tumor cells.  
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2.10.3 Glutamate  
In pre-testing we have observed changes in the distribution of CD8+ T cell 
subpopulations in Grm1 mice compared to wt mice. In the literature, it is described that 
melanocytes with aberrant Grm1 expression release high levels of glutamate in vivo 
and in vitro. Therefore, we hypothesize that elevated glutamate concentrations in Grm1 
mice will lead to alterations in CD8+ T cell subsets and effector activity.  
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3 Materials and methods 
3.1 Materials 
3.1.1 Mice  
The following mice strains were either purchased from specific breeding companies or 
were provided by different cooperation partners:  
• Grm1 wt: Tg(Grm1)EPv mice were provided by Anja Bosserhoff (Erlangen, 
Germany) and further bred in-house in our specific pathogen-free facilities. Only 
male mice were used for our experiments.  
• Grm1 Tbet-/-: Tg(Grm1)EPv mice (provided by Anja Bosserhoff, Erlangen, 
Germany) were crossbred with B6.129S6-Tbx21tm1 Glm/J mice (#004648, 
Jackson Laboratory) in-house in our specific pathogen-free facilities. Only male 
mice were used for our experiments.  
• Four-week-old male wt C57BL/6J mice (B6) were obtained from Charles River 
Laboratory (Sulzfeld, Germany). They were applied as control or reference mice 
in the Grm1 project. Furthermore, they were used in the glutamate project.  
• Four-week-old female BalbNeuT mice were provided by Christoph Klein 
(Regensburg, Germany) and served as donors for mammary gland 
transplantation.  
• Four-week-old female wt Balb/cJ mice were purchased from Charles River 
Laboratory (Sulzfeld, Germany) and served as recipient mice in experiments for 
the BalbNeuT model. Furthermore, they were used in the glutamate project.  
Before starting the experiments, all animals purchased by breeding companies were 
housed for at least one week in our specific pathogen-free facility with access to food 
and water ad libitum. Animal experiments were performed according to regulations of 
Upper Palatinate, Germany.  
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3.1.2 Reagents, cytokines and kits 
• InVivoMab anti-mouse NK1.1 clone PK136 (BE0036, BioXCell) 
• MultiScreen-IP, 0,45µm, transparent, steril, Elispot Assay (MAIPS4510, Merck) 
• Mouse IFN-γ ELISpotBASIC (ALP) (3321-2A, Mabtech)  
• NK Cell Isolation Kit II, mouse (130-096-892, Miltenyi) 
• 1-Step™ NBT/BCIP Substrate Solution (34042, Thermo Scientific) 
• Recombinant Human IL-15 Protein (247-ILB-025, R&D systems) 
• Recombinant Mouse IL-15R alpha Fc Chimera Protein, CF (551-MR-100, R&D 
systems) 
• mGluR1 (extracellular) polyclonal antibody (BML-SA610-0050, Enzo 
Lifesciences) 
• Histofine simple stain max goat anti-rabbit polymer-HRP (414141F, Nichirei 
Biosciences) 
• AEC+substrate-chromogen solution (K346111-2, Agilent DAKO) 
• Mayers Haemalaum (109249; Merck Millipore) 
• Buffer EL (79217, Qiagen) 
• Foxp3 / Transcription Factor Staining Buffer Set (00-5523-00, eBioscience) 
• Fixable Viability Dye eFluor506 (65-0866-14, eBioscience)  
• NK Cell Isolation Kit, mouse (130-115-818, Miltenyi) 
• Cell Proliferation Dye eFluor™ 450 (65-0842-85, eBioscience) 
• Annexin V Apoptosis Detection Kit APC (88-8007-74, eBioscience) 
• CellTrace Far Red Cell proliferation dye (C34564, ThermoFisher Scientific) 
• YOYO-1 Iodide (Y3601, ThermoFisher Scientific) 
• mTRAPTM Lysis Buffer (29011, Active Motif) 
• Rat anti-Mouse CD107a (1D4B, RUO), PE (558661, BD Pharmingen) 
• GolgiPlug: Protein Transport Inhibitor (Containing Brefeldin A) (555029, BD 
Bioscience) 
• GolgiStop: Protein Transport Inhibitor (Containing Monensin) (554724, BD 
Bioscience) 
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• Naive CD8a+ T Cell Isolation Kit, mouse (130-096-543, Miltenyi) 
• Cell Proliferation Dye eFluor™ 670 (65-0840-85, eBioscience) 
• Anti-mouse CD3e Monoclonal Antibody (145-2C11) (14-0031-86, eBioscience) 
• Anti-mouse CD28 Monoclonal Antibody (37.51), Functional Grade (16-0281-82, 
eBioscience) 
• Mouse IL-2 (130-094-055, Miltenyi) 
• Purified NA/LE Hamster Anti-Mouse CD178 (MFL3) (555290, BD Bioscience) 
• L-glutamic acid monosodium salt hydrate (G5889, Sigma Aldrich) 
• CD8a+ T Cell Isolation Kit, mouse (130-104-075, Miltenyi) 
• Fura-2, AM, cell permeant (F1201, ThermoFisher Scientific) 
• PluronicTM F-127 (Thermo Fisher Scientific) 
• Naive CD4+ T Cell Isolation Kit, mouse (130-104-453, Miltenyi) 
• RT2 qPCR Primer Assay Plate (24 plates) (CLAM35809, Qiagen) 
• RT² SYBR Green qPCR Mastermix (24) (330503, Qiagen) 
3.1.3 Buffers, Media 
• DPBS, no calcium, no magnesium (14190-094, Gibco/ThermoFisher Scientific) 
• 10x MACS: 27,5g BSA, 22ml EDTA, 500ml DPBS 
• 1% PFA in PBS pH 7,4 
• RPMI 1640 (31870-074, Gibco) 
• Fetal Bovine Serum (26140079, Gibco) 
• L-Glutamine solution (G7513, Sigma Aldrich) 
• Penicillin-Streptomycin (P0781, Sigma Aldrich) 
• 2-Mercaptoethanol (50 mM) (31350010, Gibco) 
• Ringer solution: 140mM NaCl, 5mM KCl, 2mM CaCL2, 100µM Glycine, 10mM 
HEPES, pH 7.35 
3.1.4 Cell lines  
• Yac-1 (86022801; Sigma-Aldrich): suspension cells, mouse lymphoma, induced 
by inoculation of Moloney leukaemia virus into a new-born A/Sn mouse 
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• A20 (ATCC TIB-208, ATCC): suspension cells, reticulum cell sarcoma, 
Balb/cAnN 
3.1.5 Flow cytometry antibodies 
 Antibody  
(Clone) 
Species 
Reactivity 
Company Cat.nr. 
FITC NK1.1 M eBioscience 11-5941-85 
 CD8a (53-6.7) M eBioscience 11-0081-85 
 CD11c (N418) M eBioscience 11-0114-85 
 CD127 (A7R34) M eBioscience 11-1271-85 
 CD4 (GK1.5) M eBioscience 11-0041-86 
 CD28 (CD28.2) M eBioscience 11-0289-41 
 CD69 (H1.2F3) M eBioscience 11-0691-81 
PE CD335 (NKp46) (29A1.4) M eBioscience 12-3351-82 
 TCR gamma/delta (eBioGL3 
(GL-3, GL3)) 
M eBioscience 12-5711-82 
 FOXP3 (NRRF-30) M eBioscience 12-4771-82 
 CD4 (RM4-5) M eBioscience 12-0042-83 
 CD8a (53-6.7) M eBioscience 12-0081-83 
 EOMES (Dan11mag) M eBioscience 12-4875-82 
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 Rat IgG2a kappa Isotype 
Control (eBR2a) 
M eBioscience 12-4321-80 
 CD25 (PC61.5) M eBioscience 12-0251-81 
 NK1.1 (PK136) M eBioscience 12-5941-83 
PE-Cyanine7 CD27 (LG.7F9) M eBioscience 25-0271-82 
 CD44 (IM7) M eBioscience (25-0441-82 
 Ly6G/Ly-6C (Gr-1) (RB6-
8C5) 
M eBioscience 25-5931-82 
 CD4 (RM4-5) M eBioscience 25-0042-82 
 CD8a (53-6.7) M eBioscience 25-0081-82 
 T-bet (eBio4B10 (4B10)) M eBioscience 25-5825-82 
 Mouse IgG1 kappa Isotype 
Control (P3.6.2.8.1) 
M eBioscience 25-4714-80 
 CD134 (OX40) (OX-86) M eBioscience 25-1341-80 
APC KLRG1 (2F1) M eBioscience 17-5893-82 
 CD4 (GK1.5) M eBioscience 17-0041-83 
 CD8a (53-6.7) M eBioscience 17-0081-83 
 CD25 (PC61.5) M eBioscience 17-0251-82 
 CD335 (NKp46) (29A1.4) M eBioscience 17-3351-82 
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 CD152 (CTLA-4) (UC10-
4B9) 
M eBioscience 17-1522-82 
 Armenian Hamster IgG 
Isotype Control 
(eBio299Arm) 
M eBioscience 17-4888-82 
 
APC-eFluor780 
(APCCy7) 
CD3e (145-2C11) M eBioscience 47-0031-82 
 CD4 (GK1.5) M eBioscience 47-0041-82 
eFluor 450 (PB) CD11b (M1/70) M eBioscience 48-0112-82 
 CD62L (L-Selectin) (MEL-14) M eBioscience 48-0621-82 
 CD4 (RM4-5) M eBioscience 48-0042-82 
 CD8a (53-6.7) M eBioscience 48-0081-82 
 CD279 (PD-1) (RMP1-30) M eBioscience 48-9981-80 
 Rat IgG2b kappa Isotype 
Control (eB149/10H5) 
M eBioscience 48-4031-82 
 CD25 (PC61.5) M eBioscience 48-0251-82 
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3.2 Methods  
3.2.1 Evaluation of tumor formation and – progression in Grm1 mice  
Grm1 mice spontaneously develop melanomas in hairless skin regions at a certain 
time point in their development. Bosserhoff and colleagues established a specific 6-
point grading system allowing the categorization of melanomas at different stages213. 
For evaluation ears, tail and anus are considered (Fig. 9). At grade 1, the first 
melanomas are palpable, but not visible. Grade 2 describes small, clearly visible 
melanomas on the ears. This stage declares the “tumor onset” for experiments which 
will be described later. Grade 3 – 5 includes melanomas on the ears, as well as 
thickenings and tumor knots at the tail and perianal regions. Strong tumor formation 
with risk of ulcerations is specified as tumor grade 6. At this stage mice are killed to 
avoid any serious effects of tumor burden.  
 
Figure 9: Grading system for evaluation of tumor formation and –progression in Grm1 mice 213.  
Grade 1: palpable, but invisible melanomas on the ears; grade 2: “tumor onset” – small, clearly visible 
melanomas on the ears; grade 3-5:  melanomas on the ears and thickenings at the tail and perianal regions; 
grade 6: tumor formation with risk of ulcerations. 
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3.2.2 IFNγ- Elispot of NK cells  
On day 1, a MB Multiscreen PVDF plate (MAIPS4510, Millipore) was pre-coated with 
15µg/ml IFNγ antibody (3321-2A, vial 1, green top, AN18, Mabtech) and incubated 
overnight (o/n) at 4°C. The next day (day 2), the plate was washed with PBS followed 
by blocking with full medium for 2 hours (h) at room temperature (RT). NK cells were 
isolated from spleens by using the NK cell isolation Kit II (130-096-892, Miltenyi). 
Effector and target cells were set up at different E:T ratios with a target cell number of 
50,000 cells per well; the ratios were set at 1:1, 2:1 and 3:1. Cells were incubated 
together in the plates o/n at 37°C. On day 3, the plate was washed with PBS followed 
by incubation with 1 µg/ml detection antibody (3321-2A, vial 2, yellow top, R4-6A2, 
Mabtech) for 2h at RT. The antibody was diluted in PBS containing 0.5% FCS. Before 
and after addition of 100µl streptavidin-alkaline phosphatase conjugate (3321-2A, vial 
3, white top, Mabtech) to each well, for 1h at RT in the dark, the plate was washed 
again with PBS. 100µl 1-Step NBT/BCIP (nitro-blue tetrazolium chloride/5-bromo-4-
chloro-3'-indolyphosphate p-toluidine salt) substrate solution (34042, ThermoFisher 
Scientific) was added to each well and incubated for 7 minutes at RT in the dark. The 
reaction was stopped with tap water followed by three further washing steps with water. 
The plate was left to dry o/n at RT. On day 4, spots were counted with a specific Elispot 
reader (EliSpot Robotic System ELROB05i, AID Advanced Imaging Devices GmbH 
Straßberg).  
3.2.3 Treatment of Grm1 mice with NK cell-depleting antibody PK136 
To deplete NK cells in Grm1 mice, 5 week-old animals received an intraperitoneal (i.p.) 
injection of 200µg PK136 antibody, which is considered day 0 (BE0036, BioXCell). At 
this time, Grm1 mice did not yet show tumor formation. The antibody had a stock 
concentration of 9.3mg/ml and was kept in PBS. At day 2, mice received a second 
application of the same NK-depleting antibody, followed by weekly injection until 
reaching tumor grade 2. After tumor detection, treatment with the NK-depleting 
antibody was stopped and tumor grade monitoring was continued for further 8 weeks.  
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3.2.4 Preparation of soluble IL-15 pre-complexed to IL-15Rα  
A cytokine–receptor complex containing a human recombinant IL-15 protein and a 
recombinant fusion protein consisting of the ectodomain of the mouse IL-15Rα-chain 
and human IgG1-Fc (IL-15Rα/Fc) were purchased from R&D Systems (Minneapolis, 
USA). IL‐15 and IL‐15Ra/Fc were resuspended in PBS solution and freshly mixed 
together at a ratio of 1:6 (IL‐15:IL‐15Ra/Fc). Before using the mixture for in vivo 
injections or in vitro experiments, it was incubated at 37°C for 30 min.  
3.2.5 Treatment of Grm1 mice with pre-complexed IL-15 
Grm1 mice were checked weekly for tumor formation. Melanomas were classified by 
the previously mentioned 6-point grading system (chapter 3.2.1). On the day of tumor 
onset, i.e. when Grm1 mice reached tumor grade 2, they received an i.p. injection of 
the IL-15/IL-15Rα/Fc complex for stimulating immune cells. One set of mice was used 
for extensive analysis of immune cell phenotypes on day 4 after the first IL-15 injection 
(chapter 3.2.7 and 3.2.8.2). Another set of mice received a second IL-15 injection on 
day 30. Tumor progression was monitored in these mice until day 60 followed by 
immune cell analysis (see chapter 3.2.7). Untreated Grm1 mice were monitored for the 
same time periods and analyzed at indicated time points. These mice served as a 
reference group.  
 
Figure 10: Experimental setup of IL-15 treatment in Grm1 mice 
3.2.6 Counting of metastases in lung and liver sections of Grm1 mice  
Small lung and liver pieces were harvested 60 days after tumor onset of Grm1 mice. 
The organs were fixed in paraformaldehyde and embedded in paraffin.  
Immunostaining was performed on 3 µm serial sections. Slides were stained with a 
purified polyclonal rabbit mGluR1 antibody (BML-SA610, Enzo Lifesciences) followed 
by a secondary Histofine simple stain max goat anti-rabbit polymer-HRP (414141F, 
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Nichirei Biosciences) for detection. Sections were exposed to an AEC+substrate-
chromogen solution (K346111-2, Agilent DAKO) complemented by visualization with 
Mayers Haemalaum (109249; Merck Millipore). Slides were analyzed and images were 
acquired with a Zeiss Axio Observer Z1 microscope (Carl Zeiss, Munich, Germany).  
3.2.7 Phenotypical analysis of different immune cell subpopulations in Grm1 
mice on day 4 and day 60  
Spleen cells were isolated as a single cell suspension on day 4 and day 60 and used 
for further immune cell analysis. One million cells per flow cytometry tube were stained 
with the Fixable Viability Dye eFluor506 (65-0866-14, eBioscience) diluted 1:1000 in 
PBS followed by further washing with MACS (PBS +BSA+EDTA) and PBS. Afterwards, 
cells were stained with antibodies listed in the following table:   
Table 3: Immune cell panels for flow cytometry analysis - surface and intracellular staining 
Fluorophore NK cells CD8+ T cells MDSCs CD4 Tregs (IC) 
FITC NK1.1 CD8 CD11c CD127 
PE NKp46 gdTCR -  Foxp3 (IC) 
PeCy7 CD27 CD44 GR-1 -  
APC KLRG1 CD4 CD8 CD25 
APCCy7 CD3 CD3 CD3 CD3 
PacificBlue CD11b CD62L CD11b CD4 
 
Flow cytometry was performed on a FACSCanto II (BD Biosciences). Data were 
analyzed using FlowJo software (Tree Star, Ashland, OR, USA). 
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3.2.8 Cytotoxicity assay of NK cells from Grm1 mice  
3.2.8.1 In vitro stimulation 
For in vitro assays, NK cells were isolated from splenic single- cell suspensions by a 
NK cell isolation kit (130-115-818, Miltenyi) with the autoMACS Pro Separator (130-
092-545, Miltenyi). Sorted NK cells were then cultured in full medium containing pre-
complexed IL-15 (8µl/ml) for 24 hours. Untreated NK cells were also cultured and used 
as control cells. The next day, Yac-1 lymphoma cells were stained with the cell 
proliferation dye eFluor450 (65-0842-85, eBioscience) allowing the later distinction 
between NK cells and Yac-1 cells. Finally, NK cells were cultured with Yac-1 cells in 
different E:T ratios (1:1, 10:1) for a further 24 hours. After harvesting, the cells were 
stained with an Annexin V Apoptosis Detection Kit APC (88-8007-74, eBioscience) and 
analyzed on the FACSCanto II.  
3.2.8.2 In vivo stimulation  
For in vivo assays, Grm1 mice were treated with pre-complexed IL-15; control mice did 
not receive the IL-15 treatment. After 4 days, spleen cells were harvested and NK cells 
were isolated with the aforementioned isolation kit. Again, Yac-1 cells were pre-stained 
with the proliferation dye followed by cultivation with NK cells in different E:T ratios 
(1:1, 10:1). After 24 hours, cells were harvested and stained with the apoptosis kit, as 
indicated above.  
3.2.9 IncuCyte®  
NK cells were isolated from spleens of Grm1 wt and B6 wt mice with the NK cell 
isolation kit (130-115-818, Miltenyi). Cells were either treated with pre-complexed IL-
15 or only with medium o/n at 37°C and 5% CO2. The next day, to later distinguish 
effector and target cells, NK cells were stained with the CellTrace Far Red Cell 
proliferation dye (C34564, ThermoFisher Scientific). Afterwards, pre-stained NK cells 
were cultured with Yac-1 lymphoma cells complemented with medium containing 
YOYO-1 iodide (Y3601, ThermoFisher Scientific); this dye stains dead cells by binding 
to the DNA of apoptotic cells. The cells were incubated for at least 24 hours in the 
Incucyte® machine (4647, Sartorius), taking fluorescence images every one to two 
54 
 
 
hours which can later be analyzed with the specific Incucyte® software (Sartorius). The 
program is able to distinguish red-colored cells demonstrating NK cells and green cells 
representing dead cells. An overlay of both colors reveals dead NK cells.  
3.2.10 Analysis and sorting of immune cell subsets at different time points after 
IL-15 treatment in Grm1 wt and B6 wt mice  
Grm1 mice were checked weekly for melanomas and characterized by the 6-point 
grading system (described in chapter 3.2.1). In the following scheme (Fig. 11) a 
timeline is given to show treatment of Grm1 mice with IL-15. Furthermore, different 
time points are shown where the analysis of immune cell subsets was performed 
(panels described in 3.2.7). Moreover, besides Grm1 mice, IL-15 treatment was given 
to B6 wt mice to evaluate differences between tumor-bearing and non-tumor-bearing 
mice.  
 
Figure 11: Timeline for treatment and analysis of Grm1 and B6 wt (reference) mice 
In addition to surface and intracellular staining of different immune cell subsets, NK 
cells were sorted using a BD FACSAria sorter (BD Biosciences). Therefore, spleen 
cells were stained with the following panel: NK1.1-PE, NKp46-APC and CD3-APCCy7. 
300 cells of NK cells were transferred into mTRAP lysis buffer containing tRNAs to 
avoid the degradation of mRNA. The cells were stored at -80°C until isolation of mRNA 
and amplification of cDNA in a whole transcriptome amplification (WTA) procedure.  
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3.2.11 Whole transcriptome amplification (WTA)  
For subsequent RT2 profiling, cDNA from sorted NK cells was isolated and amplified 
in a process called WTA according to protocols provided by AG Klein (Experimental 
Medicine, Regensburg). This method was performed by Jana Koch (Stuttgart, 
Germany). First, cells were lysed to release mRNA containing polyA tails. Biotinylated 
peptide nucleic acids (PNAs) were added which bind to polyA ends. mRNA was then 
fished by streptavidin-conjugated beads. Next, RT primers were hybridized to mRNA 
and cDNA was synthesized in a reverse transcription. After release of cDNA from 
beads, polyG tails were terminally added for following amplification of total cDNA with 
specific single CP2 primers. Obtained cDNA was finally quality control checked 
through PCR with WTA positive and negative controls, followed by re-amplification to 
gain enough material for a RT² profiler.  
3.2.12 RT² Profiler and single qPCR 
An RT² profiler assay is a multiplex PCR for detection of multiple different genes from 
different samples at the same time. For gene expression analysis from NK cells of the 
Grm1 timeline, isolated cDNA (obtained by WTA, described in chapter 3.2.11) from 
cells was added to 96-well plates pre-coated with primers for different genes which are 
listed in Table 4. Plates were ordered from Qiagen (RT2 qPCR Primer Assay Plate, 
CLAM35809, Qiagen). A ready-to-use PCR master mix (RT² SYBR Green qPCR 
Mastermix, 330503, Qiagen) was added to the wells and a qPCR was run using the 
LightCycler® 480 Instrument II (05015278001, Roche). Qiagen was recommended the 
use of different housekeeper genes and other controls for a better analysis of data. As 
housekeepers we used: GAPDH (Gadph), beta-actin (Actb), HSP90AB1 (Hsp90ab1). 
The controls were: Genomic DNA control (GDC), Reverse Transcription control (RTC) 
and PCR positive control (PPC).   
As control and confirmation of the RT² profiler assay, we additionally performed single 
qPCRs of samples with primers ordered from Qiagen:  
1. Beta-actin: Mm_Actb_1_SG (# QT00095242) 
2. Eomesodermin:  Mm_Eomes_1_SG (#QT01074332) 
3. NKG2D: Mm_Klrk1_1_SG (#QT00104363) 
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Table 4: Genes for RT2 profiler of NK cells  
Gene Gene name  Gene Gene name  
Interferon gamma  
(IFNγ) 
Ifng NKG2A Klrc1 
Granzyme B Gzmb CD244 Cd244 
Perforin Prf1 FAS Fas 
Bcl-2 Bcl2 TNF receptor Tnfrsf1 
NKG2D Klrk1 TIGIT Tigit 
NKp46 Ncr1 CTLA-4 Ctla4 
CXCR3 Cxcr3 PD-1 Pdcd1 
Eomesodermin Eomes Tbet Tbx21 
KLRG1 Klrg1 LAMP-1 Lamp1 
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3.2.13 Transplantation of mammary glands of Balb-NeuT mice to Balb/c wt mice  
The following operation was done by workers of AG Klein (Regensburg, Germany). 
Balb-NeuT donor mice were killed after the third to fifth week of life. Mammary glands 
of the right and left breasts were harvested and tissues were cut into 2x2x2 pieces that 
were stored in PBS until transplantation to recipient mice. Balb/c wt recipient mice were 
then anesthetized intraperitoneally with 5mg/kg Midazol, 0.05mg/kg Fentanyl and 
0.5mg/kg Medetomidin. After shaving and disinfection of the affected area the upper 
skin layer at mammary glands was cut medially with a specific “V” section. Mammary 
glands were removed and replaced with mammary glands of the donor mouse. The 
wound was sewn with four to six stitches and mice received a subcutaneous injection 
of an antagonist mixture (Flumazenil 0.5 mg/kg, Atipamezol 2.5mg/kg, Naloxon 1.2 
mg/kg) to awake them from anesthesia. 
3.2.14 Monitoring of primary tumor development and curative surgery  
Recipient mice were weekly monitored for tumor growth after transplantation of Balb-
NeuT mammary glands. Breast tissue and the growing primary tumor were palpated 
and tumor growth was measured with a caliper. When the tumor reached ~ 1cm, it was 
removed in the same surgical procedure as the mammary glands transplanted as 
described above (chapter 3.2.13). Recipient mice were killed at different time points 
after this curative surgery (CS) for analysis. One set of mice was killed at the day of 
CS; a second set of mice was analyzed 5 weeks after CS and a third set of mice was 
killed 17 weeks after CS. For this experiment, spleen and lung were harvested for flow 
cytometry analysis to check NK and CD8+ T cell subsets (chapter 3.2.15). A CD107a 
degranulation assay was performed to measure NK cell activity (chapter 3.2.16). 
3.2.15 Phenotypical analysis of different immune cell subpopulations in the 
Balb-NeuT model 
As mentioned above, NK cell and CD8+ T cell subsets were analyzed at indicated time 
points (CS, CS+5 weeks, CS+17 weeks). The staining procedure is described in 3.2.7 
and the following flow cytometry panels were used:  
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Table 5: Immune cell panels for flow cytometry analysis - surface staining 
 
 
 
 
 
 
 
3.2.16 CD107a degranulation assay  
For the CD107a degranulation assay, 200,000 isolated splenocytes or lung cells were 
cultured with either medium (Table 6, Condition 1: “spontaneous”) or 7,500 A20 tumor 
cells (Table 6, Condition 2: “Kill”). CD107a-PE (558661, BD Biosciences) (2.5µl/ml EV) 
was added to each well followed by incubation at 37°C for 1.5h. Afterwards, GolgiPlug 
(1µl/ml EV, 555029, BD Biosciences) and GolgiStop (4µl/6ml EV, 554724, BD 
Biosciences) were added to each condition, then incubated for a further 4h at 37°C. 
For analysis, cells were harvested and stained with the Fixable Viability Dye eFluor506 
(65-0866-14, eBioscience) diluted 1:1000 in PBS followed by staining with the following 
antibodies: CD8-FITC, CD27-PeCy7, NKp46-APC, CD3-APCCy7. Flow cytometry was 
performed using a FACSCanto II (BD Biosciences) and the data were analyzed using 
FlowJo software (Tree Star, Ashland, OR, USA). 
 
 
Flourophore NK cells CD8+ T cells 
FITC - CD8 
PE NKp46 gdTCR 
PeCy7 CD27 CD44 
APC KLRG1 CD4 
APCCy7 CD3 CD3 
PacificBlue CD11b CD62L 
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Table 6: Pipette scheme of CD107a degranulation assay 
Condition Splenocytes/ 
Lung cells 
Tumor 
cells 
Medium CD107a - 
PE 
GolgiPLUG GolgiSTOP 
1  -     
2   -    
 
3.2.17 Measurement of glutamate concentrations in serum and skin samples of 
B6 wt and Grm1 Tbet-/- mice  
Serum samples were collected from the blood of B6 wt and Grm1 Tbet-/- mice. Skin 
pieces from tails and ears of the aforementioned mice were collected as well and sent 
together with serum samples to the company MetaSysX (Potsdam-Golm, Germany), 
where they performed absolute quantification of glutamate concentrations. The 
samples were measured with an Agilent Technologies Gas Chromatography (GC) 
coupled to a Leco Pegasus HT mass spectrometer, which consists of an Electron 
Impact ionization source (EI), and a Time of Flight (TOF) mass analyzer. 
3.2.18 Analysis of differentiation and proliferation of naïve CD8+ T cells after 
addition of different concentrations of glutamate  
Naïve CD8+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit 
(#130-096-543, Miltenyi) and stained with the cell proliferation dye eFluor670 (#65-
0840-85, eBiosciences). 100,000 naïve CD8+ T cells were pipetted into a 96-well plate 
pre-coated with anti-CD3 antibody (4µl/ml). A stimulation mix containing anti-CD28 
antibody (1µl/ml), IL-2 (5µl/ml) and FasL (10µl/ml) was added. Moreover, the following 
different glutamate concentrations (final) were also added to wells: 0µM, 5µM, 10µM, 
50µM, 100µM, 500µM, 1mM, 5mM, 10mM and 50mM. After 4 days, CD8+ T cells were 
harvested and stained with the following antibodies to check for proliferation and 
differentiation: CD8-FITC, CD44-PeCy7, CD3-APCCy7 and CD62L-PB.  
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3.2.19 Calcium (Ca2+) influx  
CD8+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit (#130-
104-075; Miltenyi). 100,000 CD8+ T cells were pipetted into a 96-well plate pre-coated 
with an anti-CD3 antibody (10µl/ml). An anti-CD28 antibody (2µl/ml) was added 
followed by incubation for 3 days. After harvesting, cells were washed with Ringer 
buffer containing glycine. Magnesium was not added to the buffer because of  possible 
interference with later calcium influx. Cells were then stained with 2µM of Ca2+ indicator 
Fura-2-AM (Thermo Fisher Scientific, Waltham, USA) and 0.05% pluronic F-127 
(Thermo Fisher Scientific, Waltham, USA) for 30-45min at RT in the dark. After 
incubation, cells were washed once with Ringer solution and pipetted onto a glass 
coverslip. After attachment of cells for a few minutes, different glutamate 
concentrations were added and cells with increasing Ca2+ influx were monitored using 
a Zeiss inverted microscope (Axio Observer Z.1). Changes in intracellular free Ca2+ 
([Ca2+]i) were recorded at 2-s intervals altering the wavelength of excitation light 
between 340 and 380 nm. Ca2+ images were acquired from 20-30 CD8+ T cells using 
ZEN 2012 software (ZEISS, Jena, Germany) and analyzed with ImageJ. 
3.2.20 Annexin V / PI assay  
Naïve CD8+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit 
(#130-096-543, Miltenyi). 100,000 naïve CD8+ T cells were added to a 96-well plate 
pre-coated with an anti-CD3 antibody (4µl/ml). A stimulation mix containing anti-CD28 
antibody (1µl/ml), IL-2 (5µl/ml) and FasL (10µl/ml) was added. Moreover, the following 
different glutamate concentrations (final) were added to the wells: 0µM, 5µM, 10µM, 
50µM, 100µM, 500µM, 1mM, 5mM, 10mM and 50mM. After 4, 24 and 48 hours, CD8+ 
T cells were harvested and stained with an Annexin V Apoptosis Detection Kit APC 
(88-8007-74, eBioscience) followed by analysis of cell death using the FACSCanto II.  
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3.2.21 Analysis of activation marker expression of CD8+ T cells after addition of 
different concentrations of glutamate 
Naïve CD8+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit 
(#130-096-543, Miltenyi). 100,000 naïve CD8+ T cells were added to a 96-well plate 
pre-coated with an anti-CD3 antibody (4µl/ml). A stimulation mix containing anti-CD28 
antibody (1µl/ml), IL-2 (5µl/ml) and FasL (10µl/ml) was added. Moreover, the following 
different glutamate concentrations (final) were added to the wells: 0µM, 5µM, 10µM, 
50µM, 100µM, 500µM, 1mM, 5mM, 10mM and 50mM. After 3 days of incubation, cells 
were harvested and stained with the Fixable Viability Dye eFluor506 (65-0866-14, 
eBioscience) diluted 1:1000 in PBS followed by staining with the following antibodies 
in different panels: CD28-FITC, CD69-FITC, CD25-PE, CD8-APC, CD3-APCCy7 and 
CD4-PB.  
3.2.22 Analysis of Eomesodermin (Eomes) and Tbet expression of CD8+ T cells 
after addition of different concentrations of glutamate 
Naïve CD8+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit 
(#130-096-543, Miltenyi). 100,000 naïve CD8+ T cells were added to a 96-well plate 
pre-coated with an anti-CD3 antibody (4µl/ml). A stimulation mix containing anti-CD28 
antibody (1µl/ml), IL-2 (5µl/ml) and FasL (10µl/ml) was added. Moreover, the following 
different glutamate concentrations (final) were added to the wells: 0µM, 5µM, 10µM, 
50µM, 100µM, 500µM, 1mM, 5mM, 10mM and 50mM. After 3 days, cells were 
harvested and stained with the Fixable Viability Dye eFluor506 (65-0866-14, 
eBioscience) diluted 1:1000 in PBS followed by staining with the following antibodies: 
Eomes-PE (IC stain), Tbet-PeCy7 (IC stain), CD8-APC, CD3-APCCy7 and CD4-PB. 
3.2.23 Mixed leukocyte reaction (MLR) of B6 CD8+ T cells and Balb/c splenocytes  
Splenocytes of B6 wt and Balb/c wt mice were isolated as single cell suspensions. 
CD8+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit (#130-
104-075; Miltenyi) and stained with a cell proliferation dye eFluor670 (#65-0840-85, 
eBiosciences). Stained B6 CD8+ T cells and Balb/c splenocytes were mixed in a 1:1 
ratio in a 96-well plate. The following different glutamate concentrations (final) were 
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added to wells: 0µM, 5µM, 10µM, 50µM, 100µM, 500µM, 1mM, 5mM, 10mM and 
50mM. After 3 days, cells were harvested and stained with the Fixable Viability Dye 
eFluor506 (65-0866-14, eBioscience) diluted 1:1000 in PBS followed by staining with 
the following antibodies to check for proliferation and differentiation of CD8+ T cells: 
CD8-FITC, CD4-PE, CD44-PeCy7, CD3-APCCy7 and CD62L-PB.  
3.2.24 Analysis of activation marker expression of CD4+ T cells after addition of 
different concentrations of glutamate 
Naïve CD4+ T cells were isolated from splenocytes of B6 wt mice with an isolation kit 
(#130-104-453, Miltenyi). 100,000 naïve CD4+ T cells were added to a plate pre-coated 
with an anti-CD3 antibody (4µl/ml). A stimulation mix containing anti-CD28 antibody 
(1µl/ml) and IL-2 (5µl/ml) was added. The following different glutamate concentrations 
(final) were added to wells: 0µM, 5µM, 10µM, 50µM, 100µM, 500µM, 1mM, 5mM, 
10mM and 50mM. After 2 days CD4+ T cells were harvested and stained with the 
Fixable Viability Dye eFluor506 (65-0866-14, eBioscience) diluted 1:1000 in PBS 
followed by staining with the following antibodies: CD69-FITC, Foxp3-PE (IC stain), 
CD134-PeCy7, CD4-APC, CD3-APCCy7 and CD25-PB.  
3.2.25 Statistics 
All statistical analyses were performed using GraphPad Prism, version 7 (GraphPad 
Software, Inc., San Diego, CA, http://www.graphpad.com). Generally, differences with 
a p value ≤ 0.05 were considered to be statistically significant. However, the 
significance is further categorized dependent of the strength of significance:  
- ns = p > 0.05,  
- * = p ≤ 0.05 
- ** = p ≤ 0.01 
- *** = p ≤ 0.001 
- **** = p ≤ 0.0001 
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Depending on each experiment, different statistical tests were applied. When we 
compared two groups, e.g. a control group (untreated/ unstimulated) and a test group 
(treated/ stimulated), a simple student's unpaired t-test was performed for statistical 
analysis. This test compares two mean values with each other and determines if they 
are significantly different. The influence of different categorically independent variables 
on one continuous dependent variable were analyzed using two-way ANOVA. Different 
post-hoc tests were performed depending on the problem of the experiment. Sidak´s 
multiple comparison test was used to calculate familywise error rates by comparing the 
mean values of different conditions of one group with mean values of the same 
conditions of another group. A Tukey´s multiple comparison test was used when we 
compared mean values of every treatment with the mean values of every other 
treatment. With a Dunnett´s multiple comparison test, we compared all means with the 
mean of a control group.  
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4 Results 
4.1 Spontaneous melanoma mouse model - Grm1  
4.1.1 Activity of Grm1 NK cells was similar to B6 wt NK cells 
Since Grm1 mice spontaneously form tumors within their normal growth and 
development, we hypothesized that NK cells of tumor-bearing mice would be more 
active due to tumor antigen exposure compared to NK cells of B6 wt mice not 
developing tumors. To confirm this, we verified the amount of IFN-γ-producing NK cells 
isolated from B6 wt and Grm1 mice by an IFN-γ-Elispot (method section 3.2.2). At 
different E:T ratios, NK cells were cultivated with Yac-1 lymphoma cells for 24 hours. 
As negative controls, NK cells of both mouse strains were cultured only with medium. 
As expected, we observed that higher E:T ratios produced more positive spots (Fig.12), 
and IFN-γ-producing NK cells were only increased in the presence of tumor cells. 
Importantly, the number of IFN-γ-producing NK cells tended to be higher in Grm1 mice, 
but the difference was not significant at any of the ratios tested (p>0.05 for each 
comparison). Therefore, contrary to our expectations, Grm1 NK cells did not clearly 
show higher activity versus B6 wt NK cells. 
 
Figure 12: IFN-γ-Elispot of NK cells of B6 wt and Grm1 mice. Isolated B6 wt and Grm1 NK cells were 
cultivated o/n either alone or in co-culture with Yac-1 lymphoma cells. Next day, IFN-γ-producing NK cells 
were detected and counted as spots on Elispot plates with specific Elispot software. Within each group 
different E:T ratios were set up (1:1, 2:1, 3:1).  Statistical tests: Comparison of B6 wt and Grm1 (NK cells 
alone or cultivated with Yac-1 cells), n=2/each with triplicates, mean values with standard deviation (SD), 
two-way ANOVA, Sidak´s multiple comparisons test, p values > 0.05.  
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4.1.2 NK cell depletion in Grm1 mice had no influence on tumor onset and tumor 
progression 
In the previous experiment, we wanted to check the general activity of Grm1 NK cells 
against tumor cells in vitro. Since NK cells are a major part of tumor immune 
surveillance and control tumor onset and growth, we hypothesized that Grm1 mice 
depleted of NK cells would show an earlier tumor development and a faster tumor 
growth compared to immunocompetent mice. To confirm this, five-week-old Grm1 mice 
were repeatedly treated with the NK cell-depleting antibody PK136 (method section 
3.2.3), until they reached tumor stage 2 (the day of first tumor appearance). Grm1 mice 
that did not receive this antibody served as control mice (“untreated”). The animals 
were checked weekly for tumor formation and progression by the 6-point grading 
system described in the methods section 3.2.1. However, as it is illustrated in Figure 
13, mice which were treated with PK136 did not show significantly earlier tumor onset, 
although there was a tendency towards earlier tumor appearance (p=0.0726). 
Moreover, tumors of mice with missing NK cells did not grow faster compared to tumors 
of untreated mice (Fig. 14). Taken together, depletion of NK cells did not significantly 
reduce the time before tumor onset and tumor growth was not altered. 
 
Figure 13: Tumor onset of untreated and PK136-treated Grm1 mice. Grm1 mice repeatedly received a NK 
cell-depleting antibody PK136 until day of first tumor appearance. Untreated mice did not get antibody 
injection. Days until tumor onset were counted in both groups. No significant difference was observed. 
Statistical test: Comparison of untreated (n=19) and PK136-treated (n=12) Grm1 mice, mean values with SD, 
t-test; p=0.0726 
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Figure 14: Tumor grade monitoring of untreated and PK136-treated Grm1 mice. Grm1 mice repeatedly 
received a NK cell-depleting antibody PK136 until day of first tumor appearance. Untreated mice did not get 
antibody injection. Tumor grade was monitored for eight weeks after tumor onset (explanation of grades in 
chapter 3.2.1). No significant differences were observed at each time point. Statistical tests: Comparison 
of untreated and PK136-treated Grm1 mice at each time point, n=10, mean value with SD, Two-way ANOVA, 
Sidak´s multiple comparisons test, p values > 0.05.  
4.1.3 IL-15 treatment in Grm1 mice did not prevent tumor progression and 
metastasis formation 
We have observed that NK cells alone had no clear influence on tumor onset and tumor 
growth in Grm1 mice. IL-15 is described as a cytokine boosting the immune system 
and enhancing anti-tumor immunity in mice. With regard to the potential prevention 
effect of IL-15 against tumor progression, we thought that treatment with this cytokine 
would lead to slower tumor growth in treated (“IL-15”) mice in comparison to untreated 
mice. Moreover, we assumed a reduced metastasis formation in mice obtaining IL-15 
immunotherapy. To test this, Grm1 mice were treated two times with IL-15 within 60 
days (therapeutic schedule described in 3.2.5). Tumor growth was monitored by 
weekly classification of melanomas with the 6-point grading system (see chapter 
3.2.1). Untreated mice were controlled over the same period. As shown in Fig. 15, 
tumor growth in IL-15-treated mice was similar to untreated mice with no significant 
differences. Moreover, after 60 days, metastasis formation was analyzed in liver and 
lung sections by immunohistochemistry (Fig. 16A). In liver, IL-15 treatment tended to 
reduce metastasis events, however not significantly.  
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In addition, in lungs the number of metastases increased with IL-15 treatment, but this 
difference was also not significant (Fig. 16B). Collectively, IL-15 treatment did not lead 
to slower tumor growth or less metastasis formation in Grm1 mice.  
 
Figure 15: Tumor grade monitoring of untreated and IL-15 treated Grm1 mice. Grm1 mice were untreated or 
treated with IL-15 from day of first tumor appearance (tumor grade 2). They were checked weekly for tumor 
progression and tumor stages were graded by a 6-point grading system (see chapter 3.2.1) over a time 
period of eight weeks after tumor formation. Statistical tests: Comparison of untreated and IL-15-treated 
Grm1 mice at each time point, n=10, mean value with SD, Two-way ANOVA, Sidak´s multiple comparisons 
test, p values > 0.05. 
 
Figure 16: Investigation of liver and lung metastasis in untreated and IL-15 treated Grm1 mice on day 60. 
A. Lung metastasis stained by immunohistochemistry (IHC) with an anti-mGluR1 antibody B: Counting of 
metastasis in liver and lung sections of untreated and IL-15-treated Grm1 mice. Events per cm² were 
calculated. Statistical test: Comparison of untreated and IL-15-treated mice, mean values with SD, Liver 
(UT: n=10; IL-15: n=11, p=0.1883) and lung (UT: n=10, IL-15: n=12, p=0.3914), t-test.  
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4.1.4 IL-15 effects on CD8+ T cells, but not NK cells, four days after treatment  
Contrary to our expectation, IL-15 had no long-term effect on tumor progression and 
metastasis formation. To test if the therapy had any effect on immune cell subsets, 
CD8+ T cells and NK cells were investigated by flow cytometry (staining panel 
described in 3.2.7) four days after first IL-15 application. CD8+ T cell subpopulations 
changed significantly with IL-15 treatment, especially naïve CD8+ T cells (TN) 
decreased and central memory T cells (TCM) increased markedly (Fig.17A). NK cell 
subsets in IL-15-treated animals showed no significant differences compared to 
untreated mice (Fig. 17B). However, expression of the NK cell activation marker 
KLRG1 was increased in CD27low and CD27high NK cells after treatment with the 
cytokine (Fig.17C). Taken together, IL-15 treatment for four days led to changes in 
CD8+ T cell compartments and NK cell activity, but not in NK cell subset distribution. 
 
Figure 17: Effect of IL-15 on immune cells four days after treatment. Immune cell subsets of Grm1 mice 
were analyzed by flow cytometry four days after IL-15 injection. Untreated mice did not get antibody 
injection. A. CD8+ T cells subsets. B. NK cell subsets. C. KLRG1 expression of NK cells. Statistical tests: 
Comparison of untreated (n=9) and IL-15-treated (n=6) mice, mean values with SD, t-test, ** p ≤ 0.01,  
**** p ≤ 0.0001.  
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4.1.5 IL-15 treatment induces significant changes in CD8+ T cell and NK cell 
subsets 60 days after treatment 
Single treatment of Grm1 mice with IL-15 showed significant changes only in the 
distribution of CD8+ T cell subsets four days after injection of the cytokine. We analyzed 
immune cell subpopulations again after 60 days and two IL-15 applications 
(therapeutic schedule described in 3.2.5) to check if IL-15 has a longer-term effect on 
NK cells. CD8+ T cells showed similar changes of subsets as found four days after IL-
15 treatment. Naïve CD8+ T cells were still diminished after the second IL-15 treatment 
and central memory T cells were still increased. Again, no significant changes were 
observed in the effector T cell subset (Fig. 18A). Contrary to day 4, NK cells showed 
significant changes in all three subpopulations on day 60. Immature NK (iNK) cells 
increased in contrast to mature NK cell (mNK) subsets that were decreased (Fig. 18B). 
KLRG1 expression tended to be reduced in CD27low and CD27high NK cells, but not 
significantly (Fig.18C). Collectively, 60 days after IL-15 treatment, changes in CD8+ T 
cell and NK cell subsets were observed.  
 
Figure 18: Effect of IL-15 on immune cells 60 days after treatment. Immune cell subsets of Grm1 mice were 
analyzed by flow cytometry 60 days after IL-15 injection. Untreated mice did not get antibody injection. A. 
CD8+ T cells subsets. B. NK cell subsets. C. KLRG1 expression of NK cells. Statistical tests: Comparison 
of untreated (n=9) and IL-15-treated (n=9) mice, mean values with SD, t-test, ** p ≤ 0.01, *** p ≤ 0.001,  
**** p ≤ 0.0001.  
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4.1.6 IL-15 treatment led to higher NK cell cytotoxicity in vitro and ex vivo  
In previous experiments we observed that IL-15 treatment led to changes in immune 
cell subset distribution and their activation. IL-15 is also described as a cytokine 
stimulating NK cell proliferation as well as cytotoxicity. The latter can be measured by 
a killing assay using Annexin V/PI staining. First, we investigated the effect of IL-15 on 
the killing capacity of NK cells in vitro (method section 3.2.8). Unstimulated or IL-15-
stimulated NK cells were cultivated with Yac-1 lymphoma cells at different E:T ratios 
(1:1, 10:1). It was observed that IL-15 led to significantly higher NK cell activity 
compared to that of unstimulated NK cells. At both ratios, more dead tumor cells were 
observed when cultured with stimulated NK cells (Fig. 19A). NK cells of Grm1 mice, 
which were either untreated or stimulated with IL-15 for four days, were used in an ex 
vivo cytotoxicity assay (method section 3.2.8). NK cells were isolated from spleens and 
cultured with Yac-1 cells at different E:T ratios (1:1, 10:1). Again, NK cells that were 
stimulated with IL-15 in vivo showed higher cytotoxicity than NK cells isolated from 
mice that did not receive IL-15 treatment (Fig. 19B). Summarized, IL-15 treatment led 
to enhanced cytotoxicity of NK cells in vitro and ex vivo. 
 
Figure 19: NK cell cytotoxicity assay in vitro and ex vivo. A. in vitro assay: NK cells of Grm1 mice were 
isolated from spleens and stimulated over night with IL-15. Unstimulated NK cells were used as controls. 
NK cells were cultivated with Yac-1 lymphoma cells and killing capacity of NK cells was measured by AV/PI 
staining. B. ex vivo assay: Grm1 mice were treated with IL-15. After four days NK cells of spleens were 
isolated. NK cells of untreated mice were used as controls. NK cells were cultivated with Yac-1 lymphoma 
cells and killing capacity of NK cells was measured by AV/PI staining. Statistical tests: Comparison of 
untreated (in vitro: n=3; ex vivo n=5) and IL-15-treated (in vitro: n=3; ex vivo n=5) mice, mean values with 
SD, t-test, ** p ≤ 0.01, **** p ≤ 0.0001. 
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4.1.7 IL-15-stimulated NK cells from Grm1 mice tended to have higher killing 
capacity compared to IL-15-stimulated NK cells of B6 wt mice  
Flow cytometry analyses showed that NK cells of Grm1 mice, which were either 
stimulated with IL-15 in vitro or after IL-15 treatment of mice in vivo, had higher killing 
capacity against Yac-1 lymphoma cells compared to their control counterparts 
(unstimulated in vitro or untreated mice; see chapter 4.1.6). Moreover, we previously 
observed that Grm1 NK cells tended to be more active than NK cells of B6 wt mice 
(see chapter 4.1.1). In the following experiment, we used the Incucyte® technology of 
Sartorius to perform cytotoxicity assays on the basis of live cell imaging (method 
section 3.2.9). We compared the killing capacity of Grm1 and B6 wt NK cells towards 
Yac-1 cells. After isolation of NK cells from spleens of both mouse strains, we 
stimulated these immune cells with IL-15 o/n; unstimulated NK cells served as controls 
(-IL-15). Cytotoxicity of NK cells cultivated with Yac-1 cells were monitored for several 
days in the Incucyte® machine taking pictures every one to two hours. We repeated 
this experiment three times and in Fig. 20 one of the three experimental analyses is 
shown. Generally, we observed again a tendency that NK cells of Grm1 mice (Fig. 20, 
unfilled hexagon symbol and unfilled triangle symbol) have higher activity compared to 
NK cells of B6 wt mice (Fig. 20, filled hexagon symbol and filled triangle symbol) 
independent of stimulation with IL-15 (Fig. 20, unfilled or filled symbols). However, we 
could also see that IL-15 stimulation of NK cells led to a higher number of dead Yac-1 
cells in both mouse strains. When we selected certain time points from all three 
experiments and compared the number of dead cells, we observed no significant 
differences between activity of NK cells isolated from Grm1 or B6 wt (Fig. 21), but the 
lack of significance was likely due to the high variability in results with the assay. Taken 
together, we confirmed that IL-15 enhanced the killing capacity of NK cells, however 
the activity of NK cells of Grm1 mice only showed a tendency to be higher compared 
to NK cells of B6 wt mice.  
73 
 
 
 
Figure 20: NK cell cytotoxicity assay of B6 wt and Grm1 mice monitored by Incucyte®. NK cells of Grm1 
and B6 wt mice were isolated from spleens and stimulated o/n with IL-15. Unstimulated NK cells were used 
as controls. Next day, NK cells were stained with the CellTrace Far Red dye and were then cultivated with 
Yac-1 cells for several hours. YOYO-1 dye was added to medium to identify dead cells by intercalating into 
DNA. The Incucyte® machine took pictures every one to two hours.  
 
Figure 21: Comparison of the killing capacity of unstimulated and IL-15-stimulated NK cells of B6 wt and 
Grm1 mice at different time points. The numbers of dead cells calculated by the Incucyte software were 
compared between B6 wt and Grm1 mice at certain time points. Statistical tests: Comparison of B6 wt and 
Grm1 mice +/- IL-15, mean values with SD, n=3, Two-way ANOVA, Tukey´s multiple comparisons test, p 
values > 0.05.  
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4.1.8 IL-15 shortly boosted NK cells, but significantly reduced NK cell numbers 
after dual treatment  
In previous experiments, we could see that IL-15 was generally able to enhance the 
anti-tumor activity of NK cells shortly after treatment and the cytokine increases 
cytotoxicity in vitro and in vivo (see chapter 4.1.6). However, no significant changes in 
subpopulations were observed four days after injection in Grm1 mice (see chapter 
4.1.4). Only dual treatment of Grm1 mice with IL-15 led to significant changes in the 
NK cell subset monitored on day 60 (see chapter 4.1.5). Moreover, we could not 
observe slower tumor growth or lower numbers of metastases in Grm1 mice after 
cytokine treatment (see chapter 4.1.3). Hence, we again took a closer look at NK cells 
at different time points after IL-15 treatment. We set up a timeline in which Grm1 mice 
were treated with IL-15, like described above (chapter 3.2.5), and analyzed NK cells at 
various time points to observe changes during treatment. We hypothesized that IL-15 
is indeed efficient in boosting NK cell numbers for a short time; however, it is not able 
to maintain this effect over a longer time interval, enabling tumors to eventually grow 
and spread into lung and liver. We also treated B6 wt mice in the same procedure to 
compare the effect of IL-15 in tumor-bearing versus non-tumor-bearing mice. We 
wanted to see if changes in NK cells are only due to IL-15 treatment or if the tumor 
itself influences these immune cells.  
Firstly, we looked at total NK cells numbers in untreated and IL-15-treated Grm1 and 
B6 wt mice. A significant increase in total NK cell numbers was found four days after 
the first IL-15 injection, compared to untreated mice in both mouse strains (p<0.05). 
Within the first 29 days the amount of NK cells decreased and was enhanced again 
four days after the second administration of the IL-15 on day 30. However, on day 60 
in both mouse strains, total NK cell numbers were markedly decreased in comparison 
to untreated mice (p<0.05, Fig. 22A and 22B). Therefore, we conclude that IL-15 only 
boosts NK cells for a short time after treatment.  
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Figure 22: Total numbers of NK cells from untreated and IL-15-treated Grm1 (A) and B6 wt (B) mice at 
different time points of the Grm1 timeline.  Immune cells were isolated from spleens of Grm1 and B6 wt 
mice at different time points and NK cells were analyzed by flow cytometry. Total numbers were calculated 
by counting beads. Statistical tests: Comparison of untreated and IL-15-treated mice, mean values with SD, 
n=4-6, t-test; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
4.1.9 IL-15 led to a proportional shift to CD27low mNK cells in Grm1 mice 
After analysis of total NK cell numbers at different time points in the Grm1 timeline we 
further analyzed NK cell subsets. After the first IL-15 treatment, the percentage of 
immature NK cells (iNKs, CD11bnegCD27high) was not significantly increased in Grm1 
or B6 wt mice and continued to be similar to untreated mice for further 29 days. After 
the second IL-15 injection, proportionally more iNKs were observed in IL-15-treated 
mice than in untreated mice in both strains (Fig. 23 A and B). In Grm1 mice, the 
percentage of iNKs decreased again to levels of iNKs of untreated mice during the next 
30 days (Fig. 23A). In B6 wt mice, the percentage of iNKs continued to be significantly 
increased compared to Grm1 mice on day 60 (Fig 23B). Comparison of the total 
numbers of iNKs (Fig. 23C and D) showed a rise after both IL-15 applications, with 
decreasing numbers within the next 30 days. On day 60, the total numbers were 
decreased substantially due to the general decrease in all NK cells, as shown in Fig. 
22.  
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Figure 23: Percentages (A and B) and total absolute numbers (C and D) of immature NK cells (iNKs) in Grm1 
(A, C) and B6 wt (B, D) mice at different time points of the Grm1 timeline.  Immune cells were isolated from 
spleens of Grm1 and B6 wt mice at different time points and immature NK cells were analyzed by flow 
cytometry. Total numbers were calculated by counting beads. Statistical tests: Comparison of untreated 
and IL-15-treated mice, mean values with SD, n=4-6, t-test, * p ≤ 0.05, ** p ≤ 0.01.  
As a percentage, we did not observe differences in CD27high mature NK cells (CD27hi 
mNKs) between untreated and IL-15-treated mice four days after applications of IL-15 
(day 4 and day 34) in both mouse strains (Fig. 24 A and B). In Grm1 mice, we observed 
that several days after IL-15 application (day 29, 45 and 60), the proportion of CD27hi 
mNKs was significantly decreased compared to untreated mice (Fig. 24A). In B6 wt 
mice, IL-15 did not affect the proportion of CD27hi mNKs at each time point (Fig. 24B). 
Treatment of mice with IL-15 led to an increase in total numbers of CD27hi mNKs in 
Grm1 and B6 wt mice, as observed on day 4 and day 34 (Fig. 24C and D).  
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Within the next 30 days, the absolute numbers of CD27hi mNKs decreased below the 
levels of untreated mice, with substantial differences on day 60 in both mouse strains. 
(Fig. 24C and D).   
 
Figure 24: Percentages (A and B) and total absolute numbers (C and D) of CD27high mNK cells in Grm1 (A, 
C) and B6 wt (B, D) mice at different time points of the Grm1 timeline.  Immune cells were isolated from 
spleens of Grm1 and B6 wt mice at different time points and CD27himNK cells were analyzed by flow 
cytometry. Total numbers were calculated by counting beads. Statistical tests: Comparison of untreated 
and IL-15-treated mice, mean values with SD, n=4-6, t-test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
As a percentage, we did not observe differences in CD27low mature NK cells (CD27lo 
mNKs) cells between untreated and IL-15-treated mice four days after applications of 
IL-15 (day 4 and day 34) in both mouse strains (Fig. 25 A and B). In Grm1 mice, several 
days after IL-15 injection (day 29 and day 45), we observed proportionally more CD27lo 
mNKs in IL-15-treated versus untreated mice.  
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On day 60 the numbers were still enhanced, but not significantly (Fig. 25A). In B6 wt 
mice we found more CD27lo mNKs on day 29 in IL-15-treated mice, however on day 
60, proportionally fewer CD27lo mNKs were observed in IL-15-treated mice compared 
to untreated mice (Fig. 25B). Moreover, IL-15 treatment elevated the total numbers of 
CD27lo mNKs on day 4 and day 34 and led to a marked decrease in numbers of these 
cells on day 60 in Grm1 and B6 wt mice (Fig. 25C and D).  Collectively, while IL-15 
treatment produced a short boost to NK cells, over the longer term there was a 
significantly reduced number of these cells after dual treatment. 
 
Figure 25: Percentages (A and B) and total numbers (C and D) of CD27low mNK cells in Grm1 (A, C) and B6 
wt (B, D) mice at different time points of the Grm1 timeline. Immune cells were isolated from spleens of 
Grm1 and B6 wt mice at different time points and CD27lomNK cells were analyzed by flow cytometry. Total 
numbers were calculated by counting beads. Statistical tests: Comparison of untreated and IL-15-treated 
mice, mean values with SD, n=4-6, t-test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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4.1.10 IL-15 led to a significant increase in central memory CD8+ T cells (TCMs) 
Like NK cells, CD8+ T cells contribute to tumor immune surveillance. Therefore, we 
had a closer look at CD8+ T cell subpopulations at different time points during IL-15 
treatment. Once more, we compared Grm1 mice with B6 wt mice to look for differences 
between animals with or without tumors. We were interested in seeing whether IL-15 
is also only able to boost the adaptive part of the immune system for a short time, 
without durable effects. Like shown in Fig. 26A and B, IL-15 led to significantly greater 
total CD8+ T cell number in Grm1 and B6 wt mice four days after treatment with IL-15 
(day 4 and day 34). However, during the following 30 days after IL-15 injection, the 
CD8+ T cell numbers were decreased again in both mouse strains almost to levels of 
untreated controls. 
 
Figure 26: Total numbers of CD8+ T cells from untreated and IL-15 treated Grm1 (A) and B6 wt (B) mice at 
different time points of the Grm1 timeline.  Immune cells were isolated from spleens of Grm1 and B6 wt 
mice at different time points and CD8+ T cells were analyzed by flow cytometry. Total numbers were 
calculated by counting beads. Statistical tests: Comparison of untreated and IL-15-treated mice, mean 
values with SD, n=4-6, t-test, * p ≤ 0.05, ** p ≤ 0.01.  
In both strains, the proportion of naïve CD8+ T cells (TNs) was significantly diminished 
in mice treated with IL-15 compared to untreated mice, almost over the whole period 
of treatment (Fig. 27A and B). Only day 15 in Grm1 (Fig. 27A) and day 15 and day 29 
in B6 wt mice (Fig. 27B) showed no significant differences between untreated and IL-
15 treated mice. The total number of TNs was substantially enhanced in both mouse 
strains at day 4 and day 34 (Fig. 27C and D), In B6 wt we observed also significantly 
elevated levels at day 15, 29 and 45 (Fig. 27D).   
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During treatment, the total number of TNs of Grm1 mice declined approximately to 
levels of T cell numbers of untreated mice (Fig. 27C). 
 
Figure 27: Percentages (A and B) and total numbers (C and D) of naïve CD8+ T cells (TNs) in Grm1 (A, C) 
and B6 wt (B, D) mice at different time points of the Grm1 timeline.  Immune cells were isolated from spleens 
of Grm1 and B6 wt mice at different time points and TNs were analyzed by flow cytometry. Total numbers 
were calculated by counting beads. Statistical tests: Comparison of untreated and IL-15-treated mice, mean 
values with SD, n=4-6, t-test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
Percentages of effector T cells (Teffs) only increased shortly after IL-15 injection, 
however it seemed that this cell subset was unaffected by the cytokine during whole 
treatment. We observed similar proportions of Teffs in untreated and in IL-15-treated 
mice after several days of IL-15 injections (Fig. 28A and B). The same observation was 
made in total numbers of Teffs. After both IL-15 treatments, the total numbers 
increased significantly and decrease again to levels of Teffs from untreated mice in 
both muse strains (Fig. 28C and D).  
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Figure 28: : Percentages (A and B) and total numbers (C and D) of effector CD8+ T cells (Teffs) in Grm1 (A, 
C) and B6 wt (B, D) mice at different time points of the Grm1 timeline.  Immune cells were isolated from 
spleens of Grm1 and B6 wt mice at different time points and Teffs were analyzed by flow cytometry. Total 
numbers were calculated by counting beads. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001 
The significant decrease in the percentages of TNs (Fig. 27A and B) was correlated 
with a substantial increase in the percentages of central memory CD8+ T cells (TCMs) 
cells in both mouse strains directly after IL-15 treatment (Fig. 29A and B). This high 
proportion of TCMs stayed until day 60. Moreover, the total numbers of TCMs were 
increased with IL-15 treatment on day 4 and day 34 (Fig. 29C and D). In Grm1 mice 
(Fig. 29C) the total number of TCMs was still significantly elevated on day 60 in 
comparison to B6 wt mice (Fig. 29D) in which the total numbers of TCMs were similar 
in untreated and IL-15-treated mice. Taken together, IL-15 is able to shortly boost CD8+ 
T cell numbers and leads to the development of TCMs. 
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Figure 29: Percentages (A and B) and total numbers (C and D) of central memory CD8+ T cells (TCMs) in 
Grm1 (A, C) and B6 wt (B, D) mice at different time points of the Grm1 timeline. Immune cells were isolated 
from spleens of Grm1 and B6 wt mice at different time points and central memory CD8+ T cells were 
analyzed by flow cytometry. Total numbers were calculated by counting beads. Statistical tests: 
Comparison of untreated and IL-15-treated mice, mean values with SD, n=4-6, t-test, * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001 
4.1.11 IL-15 treatment led to decreased expression of Eomes and NKG2D in NK 
cells several days after stimulation 
In previous flow cytometry analyses we observed that IL-15 was able to induce short 
immune boosts to NK cells, however without durable effects after dual treatment of 
mice with this cytokine. Moreover, we did not see that IL-15 treatment inhibited tumor 
progression and metastasis formation. To better understand the marked decrease in 
NK cell numbers at the endpoint of analysis (day 60) and the lack of an effect on 
tumors, we investigated the gene expression of several genes related to NK cell 
development, maturation, activity, apoptosis and exhaustion at different time points 
during IL-15 treatment of Grm1 and B6 wt mice (genes listed in 3.2.12).  
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Therefore, through a collaboration with PD Dr. Philipp Renner (Robert-Bosch-
Krankenhaus, Stuttgart, Germany), cDNA was isolated from 300 sorted NK cells by 
whole transcriptome amplification (WTA). Before starting a multiplex PCR analysis 
called RT2 profiler (see method section 3.2.11 and 3.2.12), we had to exclude samples 
because of poor cDNA, as checked by quality control after cDNA isolation. 
Unfortunately, most of the genes were not ultimately analyzed because the 
housekeeping genes could not be determined, the CT values were out of range, or we 
did not get usable CT values for the genes of interest. The need to exclude samples 
using the RT² profiler approach created the problem that a full set of expression results 
was not available at each time point (day 4, 29, 34 and 60). Therefore, we decided to 
run single qPCRs with primers for the housekeeping gene β-actin and only the specific 
genes of interest, Eomes and NKG2D, as the literature indicates that exhausted NK 
cells showed reduced expression of those particular genes214. We hoped to get more 
information compared to the RT² profiler because of the higher specificity of primers 
and PCR cycle conditions in the single qPCRs. We picked out two time points (day 4 
and day 29) including one time point directly after treatment with IL-15 and a 
subsequent time point several days after treatment (Fig.30A-D). In both mouse strains, 
IL-15 treatment led to an upregulation of Eomes, as well as NKG2D, directly after 
injection (day 4). However, several days after treatment (day 29), the expression of 
those genes tended to be reduced compared to day 4. The difference was only 
significant in B6 wt mice for the expression of NKG2D (Fig. 30D). Additional samples 
have to be included to confirm the differences in the expression of Eomes and NKG2D, 
because the lack of significance is likely due to the limited numbers of available 
samples and the varying CT values within the groups resulting in high standard 
deviations. Due to time restrictions, these follow-up experiments were not performed 
as part of this thesis project.  
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Figure 30: x-fold expression of Eomes (A, B) and NKG2D (C, D) in IL-15-treated mice compared to untreated 
mice on day 4 and day 29. NK cells of Grm1 (A, C) and B6 wt (B,D) mice were sorted at different time points 
during the IL-15 treatment and cDNA was isolated by WTA. With the help of qPCRs, the x-fold expression 
of Eomes and NKG2D was calculated. Statistical tests: Comparison of the expression of IL-15-treated mice 
compared to untreated mice, mean values with SD, n=1-4, t-test, * p ≤ 0.05. Statistical tests were only 
performed where there were multiple values available.  
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4.2 BalbNeuT model 
Our work with the Grm1 model suggests that NK cells are an important immune cell 
type in tumor immune surveillance. Interestingly, we observed that CD8+ T cells alone 
are not able to kill primary tumors or prevent the formation of metastases when NK 
cells are exhausted after immunotherapy. We considered using another mouse model 
to confirm the importance of immune cells in tumor destruction and to investigate the 
special role of immune cells in immunoediting. Therefore, we investigated the possible 
usefulness of the BalbNeuT mammary gland transplantation model, which allows for 
complete removal of the primary tumor so that factors not related to the primary tumor 
can be investigated (see chapter 2.7). For this purpose, BalbNeuT mammary glands 
with neoplastic potential were transplanted into Balb/c wt mice by the Prof. C. Klein 
group as part of the FOR 2127 consortium (University of Regensburg). We did manage 
to monitor for immune cell changes in the wt mice during primary tumor development 
and then after metastases formation; these results are shown and described below. 
However, the eventual goal of these experiments after baseline testing in wt mice was 
to transplant mammary glands into immunodeficient mice to be able to dissect the 
specific role of each immune cell type that could be transferred to these mice. 
Unfortunately, there were long-term difficulties in getting the studies in immunodeficient 
mice approved by the authorities, so the experiments could not be performed in the 
limited time of this thesis project. For completeness, however, the results of the 
experiments in Balb/c wt mice that were performed during my thesis work period are 
provided in the following sections.  
4.2.1 Monitoring of primary tumor growth and curative surgery in Balb/c wt mice 
transplanted with BalbNeuT mammary glands 
With the BalbNeuT model, we wanted to investigate immunoediting processes. We 
transplanted mammary glands of BalbNeuT mice into Balb/c wt mice to change the 
microenvironment of the tumor (method section 3.2.13). The idea was to observe, if 
the cells with neoplastic potential are able to adapt to the new host and form primary 
tumors (PTs). First, we checked the time until primary tumors reached a size of ~ 1 
cm. To monitor tumor growth, mice were inspected weekly and the tumors were 
measured by palpation and with a caliper.  
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15 of 19 Balb/c wt mice transplanted with mammary glands needed 22.7 (+/- 5.364) 
weeks to form primary tumors reaching a size of 1cm (Fig. 31). Four mice did not 
develop tumors and were excluded from further analysis.  
  
Figure 31: Time between transplantation of mammary glands and curative surgery (PT ~1 cm). Mammary 
glands from four-week old BalbNeuT mice were transplanted into four-week old Balb/c wt mice. Primary 
tumor development was monitored until the tumor size reached ~1cm. n=15 (19 mice were transplanted, 4 
mice were excluded from data because of missing primary tumor onset). Mean values with SD.    
4.2.2 Transplanted mice developed lung metastases after curative surgery of the 
primary tumor   
After monitoring the primary tumor development in Balb/c wt mice transplanted with 
BalbNeuT mammary glands, we divided the mice into three different groups depending 
on further analysis time after curative surgery. Mice were analyzed for immune cell 
changes (described in sections below) or for metastasis formation either at day of 
curative surgery (CS), five weeks or 17 weeks after CS (CS+5 weeks; CS+17 weeks). 
Balb/c wt mice can develop lung metastases after transplantation of BalbNeuT 
mammary glands and subsequent development of primary tumors. In the following 
figure, numbers of visible lung metastases are shown (Fig. 32). As mentioned above, 
some mice did not develop primary tumors in two of the groups (CS and CS+17 weeks) 
and were excluded from this analysis. At the time of CS, no metastases were visible. 
Two mice developed lung metastases five weeks after CS and one mouse showed six 
identifiable metastases 17 weeks after removal of the primary tumor.  
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In this latter group we could only show one mouse (Fig. 32) because three out of five 
transplanted mice did not develop any primary tumor and therefore no metastases; 
another mouse died before analysis.  
 
Figure 32: Numbers of lung metastases at different time points after curative surgery of the primary tumor. 
Mammary glands of BalbNeuT mice were transplanted into Balb/c wt mice. After primary tumor 
development, mice were analyzed for metastasis formation at three different time points after curative 
surgery (CS, CS+5 weeks, CS+17 weeks). Mean values with SD 
4.2.3 Presence of primary breast tumors or lung metastasis did not lead to a rise 
of effector immune cells in spleen  
CD8+ T cells and NK cells are part of immune surveillance and control primary tumor 
growth and metastasis formation. Therefore, we hypothesized that immune cell 
subsets in spleen change during tumor progression and this predicted that the 
numbers of effector NK and CD8+ T cells would increase with tumor development (time 
point “CS”). After removal of the primary tumor for five weeks (time point “CS+5 weeks), 
we predicted that immune cell subsets would re-adjust to normal levels similar to their 
control group. During metastasis formation (time point “CS+17 weeks”), we 
hypothesized a renewed increase of effector immune cell subsets. To confirm our 
hypotheses, immune cells of Balb/c wt mice transplanted with BalbNeuT mammary 
glands were analyzed at the aforementioned time points. Mice, that did not receive 
transplanted mammary glands, were included as controls (“ctrl CS”, “ctrl CS+5 weeks”, 
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“ctrl CS+17 weeks”). “Untransplanted” mice were four-week-old animals that were 
investigated before transplantation and they served as a comparison group to monitor 
immune cell changes due to natural development and aging. Notably, in the following 
experiment, a statistical analysis of time point “CS+17 weeks” was not possible 
because only one transplanted animal was included, other animals did not develop 
primary tumors. Generally, we observed an increase in Teffs and TCMs in correlation 
with a decrease in TNs within natural development of mice (comparison of 
“untransplanted” mice and “ctrl” mice). However, during primary tumor development 
and metastasis formation, all three CD8+ T cell subsets did not change significantly 
compared to control mice (Fig. 33). Moreover, during development of mice, there 
tended to be fewer iNKs and CD27hi mNKs and more CD27lo mNKs were observed 
(comparison of “untransplanted” mice and “ctrl” mice), but any change was likely 
related to immunological maturation of the mice and not to tumor development. Like in 
CD8+ T cell subsets, no significant changes in subpopulations were observed in 
transplanted mice compared to control mice (Fig. 34). To sum up, the presence of 
primary breast tumors or lung metastases did not lead to the predicted increase in 
immune surveillance relevant immune cells in spleen. 
 
Figure 33: CD8+ T cell subsets in spleen at different time points of tumor progression and metastasis 
formation. Mammary glands of BalbNeuT mice were transplanted into Balb/c wt mice. After primary tumor 
development and curative surgery, CD8+ T cell subsets were analyzed by flow cytometry. Mice that were 
not transplanted with mammary glands were used as control mice. There were no significant changes 
between control mice and transplanted mice. Statistical tests: Comparison of control mice and transplanted 
mice, mean values with SD, n=5-10, t-test, p > 0.05 for all comparisons.  
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Figure 34: NK cell subsets in spleen at different time points of tumor progression and metastasis formation. 
Mammary glands of BalbNeuT mice were transplanted into Balb/c wt mice. After primary tumor 
development and curative surgery, NK cell subsets were analyzed by flow cytometry. Mice that were not 
transplanted with mammary glands were used as control mice. There were no significant changes between 
control mice and transplanted mice. Statistical tests: Comparison of control mice and transplanted mice, 
mean values with SD, n=5-10, t-test, p > 0.05 for all comparisons.  
4.2.4 Changes in NK cell subsets were observed in lungs five weeks after 
curative surgery of the primary tumor 
In previous experiments, no changes in immune cell subsets were observed during 
primary tumor growth and metastasis formation in spleens. Since metastases arise in 
lungs in the BalbNeuT model, we had a closer look at immune cells in this organ.  
We hypothesized that the subsets change in lungs in response to direct interaction with 
tumor cells. Like observed in spleens, Teffs and TCMs increased and TNs decreased 
when mice matured. Again, no significant changes were observed in each T cell subset 
in lung compared to transplanted and control mice (Fig. 35). When we looked at NK 
cell subsets in the lung, we initially could see significant differences between control 
mice and transplanted mice. Five weeks after curative surgery of the primary tumor, a 
correlating decrease in CD27hi mNKs with an increase of CD27lo mNKs was detected. 
In the group “CS+17 weeks” we observed the same trend of NK cell distribution 
changes, however any differences were small and a statistical analysis was again not 
possible because only one transplanted animal was available due to other animals not 
developing primary tumors (Fig. 36). 
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Figure 35: CD8+ T cell subsets in lung at different time points of tumor progression and metastasis 
formation. Mammary glands of BalbNeuT mice were transplanted in Balb/c wt mice. After primary tumor 
development and curative surgery, CD8+ T cell subsets were analyzed by flow cytometry. Mice that were 
not transplanted with mammary glands were used as control mice. No significant changes between control 
mice and transplanted mice were apparent. Statistical tests: Comparison of control mice and transplanted 
mice, mean values with SD, n=5-10, t-test, p > 0.05 for all comparisons.  
 
Figure 36: NK cell subsets in lung at different time points of tumor progression and metastasis formation. 
Mammary glands of BalbNeuT mice were transplanted into Balb/c wt mice. After primary tumor 
development and curative surgery, NK cell subsets were analyzed by flow cytometry. Mice that were not 
transplanted with mammary glands were used as control mice. Statistical tests: Comparison of control 
mice and transplanted mice, mean values with SD, n=5-10, t-test, * p ≤ 0.05, **** p ≤ 0.0001.  
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4.2.5 NK cell activity was enhanced in the presence of primary tumors 
CD107a is a marker for degranulation and therefore functional activity of NK cells. To 
get an impression of the activity of NK cells during tumor progression we performed a 
CD107a degranulation assay at each time point (method description in chapter 3.2.16). 
We were predicting a higher NK cell activity in the presence of primary tumors in 
transplanted mice (CS). With removal of tumors (CS+5 weeks), we assumed a lower 
activity of NK cells similar to their control groups followed by reactivation during 
metastasis formation (CS+17 weeks). We observed at the time of curative surgery (CS) 
that the expression of CD107a was enhanced in transplanted mice, compared to 
control mice in both culture conditions [“spontaneous” (splenocytes/lung cells+ 
medium) and “kill” (splenocytes/lung cells + A20 tumor cells)] in spleen and lung. 
Moreover, in cultures with A20 tumor cells (“kill” condition), NK cells of transplanted 
mice showed significantly more degranulation than NK cells of control mice (p<0.05). 
A significant change was not observed in cultures of NK cells with only culture medium 
(“spontaneous”) (Fig.37). Five weeks after removal of the primary tumor (CS+5 weeks), 
the expression of CD107a was not significantly increased in transplanted mice 
compared to control mice in both organs, neither in the “spontaneous” nor in the “kill” 
condition. In lung, the expression of CD107a tended to be lower in transplanted mice 
compared to control mice, when lung cells were cultured with A20 tumor cells (“kill” 
condition); however; the standard deviation is relatively high in the group of 
transplanted mice (Fig. 38). 17 weeks after CS, NK cells of transplanted mice tended 
to have more degranulation in spleen, compared to their control groups in the 
“spontaneous” as well as in the “kill” condition. However, statistical analyses were not 
possible due to the lack of mice with primary tumor formation; only one transplanted 
mouse was included in the analyses (Fig. 39). In lung, we observed similar results as 
shown in the lung five weeks after the curative surgery (shown in Fig. 38). Immune 
cells in the lung from transplanted mice tended to have less degranulation when 
cultured with A20 tumor cells (“kill” condition). Taken together, development of primary 
tumors (and probably metastases) leads to stimulation of NK cell activity.  
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Figure 37: CD107a degranulation assay at time point “CS” in spleen and lung. Mammary glands of BalbNeuT 
mice were transplanted into Balb/c wt mice. After primary tumor development and curative surgery, the 
CD107a-degranulation marker was analyzed by flow cytometry. Mice that were not transplanted with 
mammary glands were used as control mice. Statistical tests: Comparison of transplanted and control mice 
in the “spontaneous” and “kill” condition, mean values with SD, t-test, n=5-10, *≤ 0.05,  p ** p ≤ 0.01. 
 
Figure 38: CD107a degranulation assay at time point “CS+5 weeks” in spleen and lung. Mammary glands 
of BalbNeuT mice were transplanted into Balb/c wt mice. After primary tumor development and curative 
surgery, the CD107a-degranulation marker was analyzed by flow cytometry. Mice that were not transplanted 
with mammary glands were used as control mice. Statistical tests: Comparison of transplanted and control 
mice in the “spontaneous” and “kill” condition, mean values with SD, t-test, n=5-10.  
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Figure 39: CD107a degranulation assay at time point “CS+17 weeks” in spleen and lung. Mammary glands 
of BalbNeuT mice were transplanted into Balb/c wt mice. After primary tumor development and curative 
surgery, the CD107a-degranulation marker was analyzed by flow cytometry. Mice that were not transplanted 
with mammary glands were used as control mice. Statistical tests: Comparison of transplanted and control 
mice in the “spontaneous” and “kill” condition, mean values with SD, n=5-10, no t-test possible.   
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4.3 Glutamate 
4.3.1 Grm1 Tbet-/- mice did not show higher glutamate concentrations in serum 
and skin samples compared to B6 wt mice 
Namkoong and colleagues discovered increased glutamate release by melanoma cells 
with constitutively activated Grm1 receptors in vitro. Moreover, Shah et al. recently 
showed a higher glutamate concentration in blood plasma of mice with aberrant Grm1 
expression in melanocytes (~50mM). As we observed lower numbers of effector and 
especially memory T cells in Grm1 Tbet-/- mice in comparison to B6 wt and B6 Tbet-/- 
mice, we hypothesized that Grm1 Tbet-/- mice have elevated levels of glutamate that 
could have negative effects on the differentiation of CD8+ T cells. To test this we 
measured glutamate concentrations in serum of B6 wt and Grm1 Tbet-/- mice via the 
company MetaSysX (Potsdam, Germany). However, as shown in the left part of Fig. 
40, the concentration turned out to actually be significantly lower in serum of Grm1 
Tbet-/- mice (~50µM). Moreover, glutamate concentrations in our samples were 1000-
fold lower than in plasma of mice mentioned in Shah´s paper. Since Grm1 mice carry 
the mutation only in melanocytes, we thought that the glutamate concentration may 
only be different in skin tissues. However, when tested glutamate levels in the skin of 
B6 wt versus Grm1 Tbet-/- mice, no significant differences were observed (Fig. 40, 
right). Collectively, our Grm1 Tbet-/- mice did not show elevated concentrations of 
glutamate in serum or skin samples.  
 
Figure 40: Concentration of glutamate in serum and skin samples of B6 wt and Grm1 Tbet-/- mice. The 
company MetaSysX measured glutamate concentrations in serum (µM) and in skin samples (µg/mg) from 
B6 wt and Grm1 Tbet-/- mice. Statistical tests: Comparison of B6 wt and Grm1 Tbet-/- mice, mean values 
with SD, n=10,  t-test, *** p ≤ 0.001 
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4.3.2 High glutamate concentrations led to impaired differentiation of naïve CD8+ 
T cells  
Despite the unexpected results of the glutamate measurement in serum and skin of 
our Grm1 Tbet-/- mice, and the differences to results of Shah et al., it is likely that local 
effects (around melanocytes producing glutamate in Grm1 mice) of glutamate could 
influence immune cells, such as CD8+ T cells. We hypothesized that higher glutamate 
concentrations in local tissues with melanocytes impair differentiation of naïve CD8+ T 
cells after general T cell stimulation. Therefore, naïve CD8+ T cells were isolated from 
splenocytes of B6 wt mice and stimulated for four days with a specific mixture of 
antibodies and cytokines (anti-CD3/ anti-CD28/ IL-2/ FasL, see chapter 3.2.18); 
effector and memory CD8+ T cell subsets (TCMs and Teffs) were measured by flow 
cytometry. Into these cultures, we added different concentrations of glutamate to test 
for an effect on cell differentiation. As can be seen in the left part of Fig. 41, from 
concentrations ≥ 500µM, the number of TCMs was significantly diminished compared 
to samples without glutamate (w/o Glu). Moreover, the number of Teffs was decreased 
at higher concentrations of glutamate with significant differences at concentrations of 
10mM and 50mM (Fig. 41, right). Taken together, increasing glutamate concentration 
had dose-dependent effects on differentiation of naïve CD8+ T cells after stimulation.  
     
Figure 41: Total numbers of central memory and effector T cells after stimulation of naive CD8+ T cells with 
different concentrations of glutamate. Naïve CD8+ T cells were isolated from spleen and incubated for 4 
days with a mixture of anti-CD3/anti-CD28/IL-2/FasL and different concentrations of glutamate. Cells were 
analyzed by flow cytometry. Statistical test: Comparison of cells incubated with glutamate and samples 
incubated without glutamate, mean values with SD, n=2, two-way Anova, Dunnett´s multiple comparisons 
test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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4.3.3 High glutamate concentrations led to impaired proliferation of naïve CD8+ 
T cells after stimulation   
Stimulation and differentiation of cells is partially connected to proliferation of these 
cells. Therefore, we predicted that besides the effect of glutamate on differentiation of 
CD8+ T cells, the proliferation of TCM and Teff subsets might also be influenced by 
higher concentrations of glutamate. Like in the previous experiment, we isolated naïve 
CD8+ T cells from splenocytes of B6 wt mice. Cells were stimulated for four days with 
a specific mixture of antibodies and cytokines (anti-CD3/ anti-CD28/ IL-2/ FasL, see 
chapter 3.2.18) followed by measurement of TCMs and Teffs; different concentrations 
of glutamate were added to these cultures. As predicted, significantly fewer TCMs 
proliferate at glutamate concentrations ≥5mM compared to samples without added 
glutamate (Fig. 42, left). The numbers of proliferating Teffs also declined at these 
concentrations, due to high variability in the two experiments, these differences were 
not significant (Fig. 42, right). Taken together, increasing glutamate concentrations had 
dose-dependent effects on CD8+ T cell proliferation.  
 
Figure 42: Total numbers of proliferating central memory and effector T cells after stimulation of naive CD8+ 
T cells with different concentrations of glutamate. Naïve CD8+ T cells were isolated from spleens of B6 wt 
mice and incubated for 4 days with a mixture of anti-CD3/anti-CD28/IL-2/FasL and different concentrations 
of glutamate. Cells were analyzed by flow cytometry. Statistical test: Comparison of cells incubated with 
glutamate and samples incubated without glutamate, mean values with SD, n=2, two-way Anova, Dunnett´s 
multiple comparisons test, * p ≤ 0.05.  
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4.3.4 Ca2+ influx after addition of different glutamate concentrations 
Calcium (Ca2+) influx into cytoplasm is often associated with apoptosis of cells. To 
exclude the fact that the aforementioned effects of glutamate on differentiation and 
proliferation is due to apoptosis of cells we performed a Ca2+ influx assay (described 
in method section 3.2.19) in stimulated CD8+ T cells after addition of three different 
concentrations of glutamate (10µM, 100µM and 1mM). At each concentration, a 
mixture of responding and non-responding cells was observed. Furthermore, there 
were cells that spontaneously died, resulting in calcium influx signals before adding 
glutamate (summary in Fig. 43 A). In Fig. 43B, one reacting cell was picked out of the 
analysis to show the signal increase after addition of glutamate (red line). We also 
observed that Ca2+ influx occurred after only a few minutes of glutamate exposure, but 
not immediately. To sum up, addition of glutamate led to Ca2+ influx in CD8+ T cells, 
which could be a sign for apoptosis in these immune cells. To confirm that, we have 
done a further Annexin V/ PI staining which is described in the next section (chapter 
4.3.5). 
 
Figure 43: Ca2+ influx assay of CD8+ T cells with different concentrations of glutamate. CD8+ T cells were 
isolated from spleens of B6 wt mice and incubated for three days with anti-CD3/anti-CD28 antibodies. A 
Ca2+ influx assay was performed and monitored by fluorescence microscopy after addition of different 
concentrations of glutamate (time point of addition is illustrated by the red lines). A. Overview of all 
monitored signals. B. fluorescence change of one single CD8+ T cell after addition of different 
concentrations of glutamate.  
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4.3.5 Cell death is not responsible for effects of glutamate on CD8+ T cells 
Besides apoptosis, Ca2+ is involved in many other signaling pathways in the cell. To 
confirm that addition of glutamate actually leads to cell death in CD8+ T cells potentially 
associated with Ca2+ and that this is the reason for the observed effects in 
differentiation and proliferation (chapter 4.3.2 and 4.3.3), we performed an Annexin V/ 
PI staining.  4h, 24h and 48h after addition of glutamate we monitored the amount of 
dead cells among unstimulated and stimulated CD8+ T cells. We observed that the 
amount of dead CD8+ T cells, which were not stimulated, increased over an extended 
period of time. Stimulated cells did not show increased cell death at higher glutamate 
concentrations compared to cells without glutamate over time (Fig. 44). Therefore, the 
effect on differentiation and proliferation was not likely related to cell death at higher 
glutamate concentrations and Ca2+ likely plays a different role that is not related to our 
hypothesis and further experiments.   
 
Figure 44: Annexin V/PI staining of unstimulated or stimulated CD8+ T cells treated with or without 
glutamate. Naïve CD8+ T cells were isolated from spleens of B6 wt mice and incubated with a mixture of 
anti-CD3/anti-CD28/IL-2/FasL and different concentrations of glutamate. An Annexin V/PI staining was 
performed 4 hours, 24 hours and 48 hours after addition of glutamate and analyzed by flow cytometry.  
4.3.6 Higher glutamate concentrations led to decreased expression of 
transcription factors Eomes and Tbet  
Eomes and Tbet are key transcription factors involved in the differentiation of naïve 
CD8+ T cells to effector (Teffs) and central memory (TCMs) CD8+ T cells. In wt mice, 
expression of Tbet leads to generation of Teffs and expression of Eomes leads to 
development of TCMs. In the following experiments, we tested whether glutamate has 
effects on expression of these transcription factors.  
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We hypothesized that higher glutamate concentrations reduce the expression of 
Eomes and Tbet and therefore the differentiation into cell subsets is impaired. For this 
experiment, we isolated naïve CD8+ T cells from splenocytes of B6 wt mice. We 
stimulated them for three days with a specific mixture of antibodies and cytokines (anti-
CD3/ anti-CD28/ IL-2/ FasL, see chapter 3.2.18) and added different concentrations of 
glutamate. Afterwards, we measured the expression of Eomes and Tbet by flow 
cytometry. Data in Fig. 45 show that stimulation of CD8+ T cells generally led to clear 
expression of both transcription factors, compared to unstimulated cells. With 
increasing glutamate concentrations, the expression of Eomes went down with a 
significant difference at a glutamate concentration of 10mM. Tbet expression was 
affected at even lower glutamate concentrations; from 5mM, the expression was 
substantially diminished compared to cells without glutamate. Taken together, higher 
concentrations of glutamate decrease the expression of key transcription factors 
responsible for generation of TCM and Teff.  
 
 
Figure 45: Eomes and Tbet expression of CD8+ T cells after addition of glutamate for 3 days. Naïve CD8+ T 
cells were isolated from spleens of B6 wt mice and incubated for 4 days with a mixture of anti-CD3/anti-
CD28/IL-2/FasLand different concentrations of glutamate. Cells were analyzed by flow cytometry. Statistical 
test: Comparison of cells incubated with glutamate and samples incubated without glutamate, mean values 
with SD, n=4-5, two-way Anova, Dunnett´s multiple comparisons test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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4.3.7 Expression of different activation markers in CD8+ T cells is decreased with 
higher glutamate concentrations  
In previous experiments we observed that higher concentrations of glutamate had 
negative effects on the differentiation and proliferation of CD8+ T cells. We also 
discovered that these observations were not likely due to cell death. In the following 
experiments, we wanted to check if glutamate has any influence on classic proteins 
involved in the stimulation or activation of CD8+ T cells. We suspected that the 
expression of these markers might decrease with higher glutamate concentrations, 
resulting in impaired activation of CD8+ T cell differentiation and proliferation. Again, 
we isolated naïve CD8+ T cells from splenocytes of B6 wt mice. We stimulated them 
for three days with the same specific mixture of antibodies and cytokines as used 
previously ± different concentrations of glutamate. Afterwards, we measured the 
expression of the T cell activation markers CD28, CD69 and CD25. As shown in Fig. 
46, CD28 expression was significantly decreased with glutamate concentrations of 
10mM and 50mM. Moreover, at same concentrations, CD25 expression was also 
diminished substantially. Looking at the early activation marker CD69, a higher 
glutamate concentration of 50mM resulted in decreased expression.  
 
Figure 46: Expression of CD28, CD69 and CD25 of CD8+ T cells after addition of glutamate for 3 days. Naïve 
CD8+ T cells were isolated from spleens of B6 wt mice and incubated for 4 days with a mixture of anti-
CD3/anti-CD28/IL-2/FasL and different concentrations of glutamate. Cells were analyzed by flow cytometry. 
Statistical test: Comparison of cells incubated with glutamate and samples incubated without glutamate, 
mean values with SD, n=2-6, two-way Anova, Dunnett´s multiple comparisons test, ** p ≤ 0.01, *** p ≤ 0.001. 
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4.3.8 Higher glutamate concentrations impaired alloreaction of CD8+ T cells  
Besides the differentiation and proliferation of CD8+ T cells, we wanted to know if the 
activity of CD8+ T cells was comprised. We performed a mixed leucocyte reaction 
(MLR) with B6 wt CD8+ T cells and fully MHC allogeneic splenocytes of Balb/c wt mice 
± glutamate (method section 3.2.23). We predicted that at the highest glutamate 
concentrations the stimulation of responder CD8+ T cells by stimulator cells (Balb/c) 
would be impaired, resulting in reduced proliferation of these responder cells. As 
shown in Fig. 47, proliferation of B6 wt CD8+ T cells was enhanced after addition of 
Balb/c wt splenocytes to wells in comparison to unstimulated CD8+ T cells. Glutamate 
concentrations above 5mM resulted in a significant decrease in proliferation of 
responder cells. This means, that higher glutamate concentrations impaired 
alloreaction of CD8+ T cells, as predicted.  
 
Figure 47: MLR of B6 wt CD8+ T cells with Balb/c splenocytes (1:1) after addition of glutamate. B6 wt CD8+ 
T cells were isolated from spleens and cultivated with Balb/c wt splenocytes and different concentrations 
of glutamate for 5 days. Cell proliferation was analyzed by flow cytometry with the Fixable Viability Dye 
eFluor506. Statistical test: Comparison of stimulated cells incubated with glutamate and stimulated cells 
incubated without glutamate, mean values with SD, n=4, two-way Anova, Dunnett´s multiple comparisons 
test, * p ≤ 0.05.  
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4.3.9 Glutamate does not affect expression of CD4+ T cell activation markers 
We already observed that high glutamate concentrations had inhibitory effects on 
activation and activity of CD8+ T cells. Next, we were interested to know if this amino 
acid influences the activation of CD4+ T cells as well. Therefore, we isolated naïve 
CD4+ T cells, stimulated them similarly to CD8+ T cells ± different glutamate 
concentrations. After two days we measured the expression of three different activation 
markers. Expression of CD69 and CD25 was not changed after addition of glutamate. 
When we looked at the expression of CD134, we detected a downward trend at higher 
glutamate concentrations above 5mM, however, no significant alterations compared to 
samples without glutamate were observed. Taken together, we summarize that 
glutamate does not affect the activation of CD4+ T cells.  
 
Figure 48: Expression of CD134, CD69 and CD25 of CD4+ T cells after addition of glutamate for 2 days. Naïve 
CD4+ T cells were isolated from spleens of B6 wt mice and incubated for 4 days with a mixture of anti-
CD3/anti-CD28/IL-2 and different concentrations of glutamate. Cells were analyzed by flow cytometry. 
Statistical test: Comparison of cells incubated with glutamate and cells incubated without glutamate, mean 
values with SD, n=5, two-way Anova, Dunnett´s multiple comparisons test. 
In these experiments, we observed that high concentrations of glutamate have 
impairing effects on differentiation, proliferation and activity of CD8+ T cells, but do not 
affect CD4+ T cells.  
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5 Discussion 
NK cells and CD8+ T cells are thought to be important immune cells in tumor immune 
surveillance. They normally are capable of recognizing tumor cells and killing them by 
different mechanisms. However, cells with neoplastic potential can develop 
mechanisms to evade immune destruction and adapt to the host´s microenvironment, 
resulting in uncontrolled tumor growth and metastasis formation67,68. During this 
doctoral thesis work, using different mouse models that were specifically selected to 
mimic “natural” tumor development and metastasis, we showed the importance of NK 
cells and CD8+ T cells and the existence of immunoediting processes during natural 
tumor progression. More precisely, we showed that natural development of tumors in 
mice leads to stimulation of immune cell differentiation and activity. Not necessarily 
expectedly, this initial response ultimately resulted in the accumulation of terminally-
differentiated NK cells and CD8+ T cells that had reduced anti-tumor activities. 
Therefore, our results suggest that the immune response to developing tumors 
reduces over time, allowing metastases to eventually expand uncontrollably. Since we 
and others have previously shown in simple tumor implantation models that IL-15 
induces these immune cells to attack tumors, we tried to enhance the anti-tumor effect 
in vivo by administering IL-15 at the time of tumor onset. Unexpectedly, however, we 
found that tumor development and metastasis was not decreased with IL-15 treatment 
and moreover may have resulted in reduced NK cell and CD8+ T cell activity directed 
against tumor progression. Our work highlights the crucial differences between the 
formerly published tumor mouse models, in which tumors or tumor cells were simply 
transferred to mice, and the spontaneous natural development of tumors with regard 
to the role of the immune system and immunoediting processes by tumors. 
Furthermore, we show that immune cells of mice that were stimulated with IL-15 did 
not overcome these immunoediting processes, and rather likely induce immune 
exhaustion several days after treatment.   
A number of aspects of my research project are worth discussing in more detail. First, 
as mentioned above, previous work from other investigators in our research group 
have shown the important role for NK cells in tumor immune surveillance, but only in 
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tumor implantation or tumor seeding (intravenous infusion) mouse models211. For 
example, by using these well-known adoptive-transfer tumor mouse models, they 
showed that a lack of mature NK cells leads to the development of lung metastases 
after intravenous injection of colon carcinoma cells in mice. A marked reduction of 
metastasis formation was observed after adoptive transfer of these missing NK cell 
populations. Furthermore, IL-15 treatment of mice completely prevented the formation 
of lung metastasis after seeding of tumor cells by stimulating NK cell differentiation and 
activity211. Indeed, these experiments showed the importance of potential anti-tumor 
activities of NK cells and the beneficial effect of IL-15 in immunotherapy. However, 
critically, these experiments were conducted with tumor cells that did not develop 
naturally in the animals; rather, the implantation or seeding was performed with already 
fully developed human or mouse cancer cells, thus omitting the natural tumor 
development process. A major goal of my thesis work was therefore to extend these 
previous experiments by studying the role of NK cells and CD8+ T cells in mouse 
models that mimic the natural (e.g. spontaneous) tumor evolution process. For this 
purpose, we selected a melanoma mouse model where mice developed tumors a few 
weeks after birth because of the overexpression of Grm1 receptors in melanocytes185. 
Some experiments were also performed in the BalbNeuT model, where mammary 
glands with neoplastic potential were transplanted into wt mice at a very young age 
from which breast tumors are formed after several weeks194. Therefore, mice from the 
two different models typify, at least to some degree, natural development of primary 
tumors and the metastasis formation process. These models were the basis for my 
investigations.  
Considering this basis, I begin the discussion by first analyzing an innate part of the 
immune system, which in my thesis was essentially NK cells. Since NK cells are able 
to recognize and kill neoplastic cells without prior sensitization, we hypothesized that 
the natural development of tumors in our mice would lead to activation of NK cells. As 
it is described in the literature, one mechanism for tumors to evade recognition and 
killing by the immune system is via downregulation of MHC class I molecules on tumor 
cell surfaces that are normally necessary for the activation of cytotoxic CD8+ T 
cells121,215. Since MHC class I is also a ligand for inhibitory NK cell receptors, the 
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downregulation of these molecules, and additional signals for activating receptors on 
NK cells, could therefore lead to the activation of NK cells in our spontaneous tumor-
forming mice215. Indeed, with the help of the BalbNeuT model, we could clearly see 
that the presence of tumor cells leads to increased activity of NK cells. We observed 
that NK cells of mice with existing primary tumors (and probably also with metastases) 
have higher expression of CD107a, which is described as a functional marker for NK 
cell activity216,  compared to mice in which primary tumors were removed in a curative 
surgery. Thus, we have shown that NK cells were activated by naturally developing 
tumors. IN the furture, our observations should be further substantiated by examining 
the MHC class I expression on tumor cells. In addition, it will be critical to test whether 
activating receptors on NK cells are upregulated during tumor development and 
metastasis formation.  
To perform the previously described cytotoxic activities, immature NK cells (iNKs) have 
to be stimulated to proliferate and differentiate into effector immune cells. We assumed 
that natural tumor development would lead to accumulation of mature NK cells with 
high anti-tumor capacities. Mature NK cells can be further divided in CD27high and 
CD27low NK cells (CD27hi and CD27lo mNKs). These NK cell subsets differ in their 
cytotoxicity and cytokine production. CD27hi mNKs are highly cytotoxic and have the 
capacity to produce cytokines like IFN-γ; they might even have the ability to kill tumor 
cells which express MHC class I, because of the reduced levels of inhibitory receptors 
for MHC class I molecules110. In comparison, CD27lo mNKs are characterized  as the 
NK cell subset with reduced capacity to proliferate, lower cytotoxicity and decreased 
cytokine production114. So, we predicted that natural tumor progression would lead to 
development of CD27hi mNKs. However, in our mice (Grm1 and BalbNeuT model) we 
observed that CD27lo mNKs represented the largest subpopulation at each indicated 
time point. In Grm1 mice, we started to investigate NK cell subsets only after the first 
tumors were visible, therefore we cannot make clear statements about NK cell changes 
before versus after malignant transformation. On the other hand, in the BalbNeuT 
model, we additionally investigated NK cells before transplantation of mammary glands 
and at a very young age of mice. We observed that natural aging generally leads to 
increased numbers of CD27lo mNKs; however, at the time of primary tumor 
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development (or shortly after removal of primary tumors), mice showed significantly 
enhanced numbers of this NK cell subset. This could be explained by the activation of 
NK cells by tumor cells and the subsequent differentiation of iNKs and CD27hi into 
CD27lo mNKs. Therefore, our experiments indicate that NK cells do show evidence of 
responding to the presence of developing tumors.  
We hypothesized at the beginning of our study that immune cells, like NK cells, are 
able to recognize and kill malignant cells to prevent tumor development or at least 
metastasis formation. However, the observed long-term elevation in levels of those 
terminally-differentiated CD27lo mNKs that have lower anti-tumor capacities could help 
to explain the substantial primary tumor and metastasis burden in our Grm1 mice. 
Moreover, the apparent dominance of CD27lo mNKs could lead to reduced tumor 
immune surveillance in the longer-term and would help to explain the development of 
breast tumors and lung metastases in mice transplanted with BalbNeuT mammary 
glands. However, we also observed that not all recipient mice developed tumors within 
the time-frame of our experiment. Different reasons are possible for this phenomenon. 
One possibility is that errors during the mammary gland transplantation procedure 
could lead to false positioning of the glands resulting in a lack of tumor development. 
Furthermore, it is conceivable that not all BalbNeuT mice are equally perfect donors 
for mammary glands. It is also possible that the immune system of some mice 
overcame immunoediting processes and is so powerful that malignant cells could be 
destroyed before development of primary tumors. Taken together, prevention of tumor 
development and metastasis formation can only be guaranteed by effector immune 
cells with high anti-tumor capacities. To further confirm our findings, future experiments 
should evolve transplanting BalbNeuT mammary glands into immunodeficient mice to 
check if tumors can rise more frequently and grow faster when distinct immune cell 
types, like NK cells, are missing.   
As alluded to before, researchers from our group have previously reported that IL-15 
treatment of mice prevented metastasis formation in lungs after the adoptive transfer 
of tumors using the a tumor cell “seeding” model. They observed in these earlier 
experiments that IL-15 treatment led to the development of immature NK cells and 
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mostly CD27hi mNKs211. Since, these latter NK cells are a subset characterized by their 
high cytotoxicity, and cytokine production, the prevention of metastases in this model 
makes scientific sense. In my thesis work, we wanted to confirm these results in mice 
with naturally developing tumors. We hypothesized that IL-15 treatment would 
stimulate the accumulation of CD27hi mNKs with strong anti-tumor capacities, leading 
to reduced primary tumor and metastasis burden. In my thesis work, we observed 
initially that IL-15 treatment of Grm1 mice with natural tumor development boosted total 
NK cell numbers and increased their killing capacities in vitro and in vivo for a limited 
time; however, in the long run, it unexpectedly rather resulted in significantly increased 
levels of NK cells with less anti-tumor activities (CD27lo mNKs)217. Consistent with this 
result, IL-15 treatment in the spontaneous (natural) tumor model did not lead to slower 
tumor growth or less liver and lung metastases. The different outcome in tumor 
progression observed in past and present experiments could be explained by the 
different settings of these two tumor models (“seeding” model versus natural tumor 
development). One consideration in this respect is that in the “seeding” model, IL-15 
was injected into mice before injection of tumor cells. Therefore, CD27hi mNKs were 
not under the influence of tumor editing processes and therefore were able to kill 
subsequently infused tumor cells. In contrast, in the mice with the natural tumor 
development, IL-15 was first given when tumors became visible initially. Since it takes 
time to recognize the first tumors in this melanoma model, and they only become visible 
once they are firmly established, it is possible that cells such as NK cells, but also other 
immune cells responsible for tumor immune surveillance, like CD8+ T cells (discussed 
later), have already been immune-edited to some degree and the IL-15 treatment is no 
longer effective. Our results would therefore support the hypothesis that tumors evolve 
the ability to alter the effects of e.g. IL-15 treatment on NK cell differentiation via 
immunoediting. Another interesting possibility to explain the lack of anti-tumor effect in 
the Grm1 mouse model could relate to the preferential expansion of the CD27lo mNKs 
under the influence of early spontaneous tumor development. Interestingly, our use of 
IL-15 treatment after tumor establishment could actually have further enhanced the 
disproportional expansion of these less effective tumor-killing cells. A further indication 
that natural tumor development could influence the effect of IL-15 on NK cells is the 
comparison of our experiments in Grm1 versus B6 wt mice. Consistent with this idea, 
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IL-15 treatment in Grm1 mice led to significantly more CD27lo mNKs compared to the 
development of CD27hi mNKs in B6 wt mice. Therefore, my thesis work shows that IL-
15 treatment is inefficient in mice with natural tumor development, at least when 
applied after tumors have already developed, and this may be related to selective 
expansion of CD27lo mNKs that are not effective at preventing further tumor growth 
and metastasis formation. These results may have implications in humans, when 
considering treatment with IL-15 to boost anti-tumor effects.  
When we treated the Grm1 mice with IL-15, we assumed that the repeated 
administration of the cytokine would lead to a permanently increased level of NK cells. 
However, we actually made the observation that repeated IL-15 treatment in Grm1 
mice, as well as in B6 wt mice, led to significantly decreased total numbers of NK cells 
over time. Our results are consistent with a study by Felices et al., showing that besides 
initial proliferation and expansion of NK cells, multiple treatment with IL-15 can 
decrease the viability of NK cells and reduce tumor control218. With our observation, 
we then hypothesized that stimulation with IL-15 results in the exhaustion of NK cells 
and probably their clearance by apoptosis. Alvarez and colleagues recently showed 
that NK cells exhaust after sustained proliferation, which impairs anti-tumor activity that 
is associated with a downregulation of the transcription factor Eomes and the activating 
NK cell receptor NKG2D214. With, albeit, a small number of samples, our hypothesis of 
NK cell exhaustion is supported by gene expression analyses of these genes showing 
the downregulation several days after IL-15 treatment. Taken together, we have shown 
that natural tumor development influences the maturation and activity of NK cells 
leading to terminally-differentiated cells with a reduced capacity to kill tumor cells. 
Furthermore, IL-15 treatment of mice shows exhaustion effects on NK cells rather than 
beneficial effects on anti-tumor activities.  
Besides NK cells we also investigated the adaptive part of the immune system. We 
studied the role of CD8+ T cells in the context of natural tumor development. Since we 
assumed that immunoediting processes take place in mice with natural tumor growth, 
we hypothesized that the presence of malignant cells does not activate CD8+ T cells. 
As mentioned above, one mechanism is the downregulation of MHC class I molecules 
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on tumors cell surfaces resulting in a lack of stimulation of CD8+ T cell activity. 
Moreover, tumor cells can express ligands for immune checkpoint proteins on CD8+ T 
cells, leading to inactivation and exhaustion of these immune cells28,219. Like expected, 
we observed that the development of tumors in our mice did not change the proportions 
of CD8+ T cell subsets. We have seen in both of our mouse models that naïve CD8+ T 
cells are the predominant subpopulation over time. Thus, CD8+ T cells did not 
overcome immunoediting processes to be activated to kill naturally developing tumor 
cells. In future experiments, we could further investigate and confirm immunoediting 
processes, e.g. by gene expression analyses of tumor and immune cells. For instance, 
on tumor cells, we could check the expression of MHC class I molecules or immune 
checkpoint ligands (e.g. PD-L1) at different time points during tumor development and 
IL-15 treatment. Furthermore, immunosuppressive molecules released by tumor cells 
could be determined in the tumor microenvironment. Additionally, on immune cells, the 
expression of the corresponding immune checkpoint proteins or the expression of 
“death” receptors (Fas, TRAIL) could be investigated220. Another point that we must 
consider in this discussion is that the assumed “tumor antigens” in our spontaneous 
cancer models may simply not be immunogenic, thus not stimulating a CD8+ T cell 
response. If this is the case, then we would need to consider to use other models where 
different tumor-specific antigens are expressed and known to stimulate CD8+ T cells.  
It is described in the literature, that CD8+ T cells migrate away from tumors to the 
spleen or lymph nodes after activation within the tumor microenvironment and lose 
their capacity to proliferate (until they were stimulated with exogenous compounds)221. 
Considering the possibility, we treated our Grm1 mice with IL-15 and hypothesized that 
the treatment stimulates CD8+ T cells to proliferate, differentiate into effector immune 
cells and perform anti-tumor activities. We observed that administration of IL-15 led to 
proliferation of CD8+ T cells, which was evident by the significant increase in total T 
cell numbers. Moreover, after IL-15 treatment the proportion of naïve CD8+ T cells 
decreased simultaneously with an increase in central memory CD8+ T cells (TCMs). 
Other research groups have also made this same observation64,144,222,223. TCMs are, 
similar to CD27lo mNKs, terminally-differentiated cells with reduced anti-tumor 
activities. This could further help to explain why tumors and metastases are eventually 
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able to grow uncontrollably in Grm1 mice. O summarize, tumors appear to develop 
mechanisms to escape immune recognition and killing by CD8+ T cells through 
different immunoediting processes, especially in the models we used where the 
immune system is exposed to the entire natural neoplasm development process. As 
already discussed for NK cells, IL-15 treatment of mice did not overcome these evasive 
mechanisms, and may even result in the development of terminally-differentiated 
TCMs that have reduced anti-tumor capacities.  
Glutamate is the natural ligand of the Grm1 receptor and is released in higher amounts 
by melanocytes that show overexpression of this receptor188,210. During experiments 
with Grm1 Tbet-/- mice, we coincidentally observed that these mice showed reduced 
numbers of effector (Teffs), and especially central memory (TCMs) CD8+ T cells 
compared to B6 wt and B6 Tbet-/- mice. We used Tbet-deficient mice because this 
transcription factor is normally involved in the differentiation of NK cells and CD8+ T 
cells and we originally wanted to study tumor progression in mice with altered immune 
cell differentiation. Nonetheless, we hypothesized that glutamate concentrations would 
be elevated in our Grm1 Tbet-/- mice, which could possibly affect the development of 
CD8+ T cells and consequently their killing capacity against melanoma cancer cells. 
However, measurements of glutamate concentrations in serum and skin samples of 
B6 wt and Grm1 Tbet-/- mice did not show increased in vivo levels of glutamate. Since 
during measurements the company that performed the testing informed us that they 
had some problems in determining the glutamate concentrations, we took a critical look 
at the authenticity of the measured concentrations. This was especially interesting to 
us because measurements in the Grm1 mice mentioned in Shah´s paper from 2019 
showed 1000-fold higher glutamate concentrations210. The only potential explanation 
we could find is that Shah et al. measured glutamate in plasma versus serum in our 
experiments. Unfortunately, we have not been able to determine the cause for this 
discrepancy, and did not have the opportunity to repeat the measurements in plasma 
instead of serum.  
Nonetheless, we continue to assume despite our inability to see higher systemic 
glutamate levels in Grm1 mice, that at least local tissue concentrations of glutamate 
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around areas of melanocytes must be higher in these mice and could be influencing 
the immune response to melanoma tumor cells. Therefore, we remained interested in 
the potential general effect of glutamate on CD8+ T cells. To examine this aspect, we 
tested a wide range of glutamate concentrations with immune cells from B6 wt mice in 
in vitro experiments. In general, to be sure that we could be sensitive to all possible 
effects, we added glutamate in a wide range of concentrations (0µM – 50mM). In those 
experiments, we observed that high concentrations of glutamate do impair the 
differentiation and proliferation of CD8+ T cells. We found that these concentrations led 
to reduced numbers of TCMs and Teffs, which could be associated with the reduced 
expression of the activation markers CD25, CD28 and CD69 at higher glutamate 
concentrations. We also observed that CD8+ T cells that were cultured with high 
glutamate concentrations showed a decreased response towards fully MHC disparate 
splenocytes from allogeneic mice; therefore, glutamate also impairs typical allogeneic 
immune response activity, which could be relevant in the case where cancers are 
expressing tumor-specific antigens. Moreover, differentiation of CD8+ T cells depends 
on key transcription factors like Eomes, and we found that the expression of this gene 
was decreased at higher glutamate concentrations. The question remains whether 
these results could contribute to the end-effect of lower numbers of Teffs and TCMs in 
Grm1 Tbet-/- mice (assuming that the Grm1 mutation leads to high glutamate 
concentrations surrounding melanocytes in these mice). In addition to these 
experiments, we also tested whether glutamate affects in the activation of CD4+ T cells, 
but no effect was detected. We therefore conclude from these experiments with 
glutamate that high concentrations of this amino acid have the ability to interfere with 
the maturation and activity of CD8+ T cells, but not CD4+ T cells. Further analyses of 
experiments in Grm1 Tbet-/- mice could show if the impairment of CD8+ T cells leads to 
altered tumor progression and metastasis formation. However, these in vivo 
experiments are very time consuming and therefore beyond the scope of my thesis 
work.  Nonetheless, since Grm1 mutations are found in different human cancer types, 
our findings are relevant and help to better understand the potential role and actions 
of the immune system, especially of CD8+ T cells, in these cancer patients in the 
context of increase glutamate levels.  
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In summary, in my doctoral thesis I investigated and confirmed a role for NK cells and 
CD8+ T cells in tumor immune surveillance and showed that there is a difference in this 
role depending on whether the tumor and immune system evolved in the setting of 
“natural” tumor development. This work supports the hypothesis that immunoediting 
processes do likely occur during natural tumor development. Moreover, I demonstrated 
that IL-15 treatment in mice with natural tumor development does not show beneficial 
effects over the long-term, which is contrary to what has been reported in adoptive-
transfer tumor models. This research provides insight into how innate and adaptive 
immune responses may affect the growth and metastasis of cancer.  
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7 Appendix 
7.1 List of abbreviations 
Abbreviation Description 
NCDs Noncommunicable diseases 
IARC International Agency for Research on Cancer 
UV Ultra violett 
Fig figure 
EMT epithelial mesenchymal transition 
DTCs disseminated tumor cells 
mABs Monoclonal antibodies 
ADCC antibody-dependent cell cytotoxicity 
NK cells Natural killer cells  
APCs Antigen-presenting cells 
MHC Major histocompatibilty comlex  
CTLs Cytotoxic lymphocytes 
EGFR Epidermal growth factor receptor 
CTLA-4 Cytotoxic T lymphocyte antigen 4 
PD-1 Programmed death-1 
LAG-3 Lymphocyte antigen gene 3 
PD-L1 Programmed death ligand 1 
CD Cluster of differentiation 
FDA Food and Drug Administration 
IFN Interferon 
γ gamma 
CAR Chimeric antigen receptor 
TAA Tumor-associated antigens 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
Cas9 Caspase 9 
4th Forth  
132 
 
 
IL Interleukin 
Tregs Regulatory T cells 
MDSCs Myeloid derived suppressor cells 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
DCs Dendritic cells  
α alpha 
TGF Tumor growth factor 
β beta 
TNF Tumor necrosis factor 
DAMPs Danger associated molecular patterns 
TSA tumor-specific antigens 
VEGF Vascular endothelial froth fatcor 
IDO Indoleamine 2,3-dioxygenase  
% percentage 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
IP-10 Interferon gamma-induced protein 10 
KIRs killer immunoglobulin-like receptors 
Ly49 Membrane C-type lectin-like receptors 
HLA Histocompatibility antigen 
ITIMs immune receptor tyrosine-based inhibitory motifs 
KLRG1 Killer cell lectin-like receptor subfamily G member 1 
ITAMs through immune-receptor tyrosine-based activating motifs 
NCRs Natural cytotoxicity receptors 
neg negative 
pos positive 
iNK Immature NK cells 
mNKs Mature NK cells  
hi high 
lo low 
γc Common gamma chain 
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TCR T cell receptor 
TN Naïve T cell 
TSCM Stem cell memory T cell 
TCM Central memory T cell 
TEM Effector memory T cell 
Teff Effector T cell 
CCR7 C-C chemokine receptor 7 
TILs tumor infiltrating lymphocytes 
MCA methylcholanthrene 
Ig Immunoglobulin 
Grm1 Metabotropic glutamate receptor 1 
kb kilobase 
Dct dopachrome tautomerase 
IP3 Inositol triphosphate  
DAG diacylglycerol 
wt Wildtype  
RAG Recombination activating gene  
-/- Knockout (KO) 
Glu glutamate 
CNS Central nerve system 
µM micromolar 
mGluR Metabotropic glutamate receptor 
iGluR Ionotropic glutamate receptor 
NMDAR N-methyl-D-aspartate receptors 
AMPA 2-amino-3-hydroxy-5-methyl-oxazole-4-propionic acid 
KA kainic ammonia acid 
M Molar 
mM millimolar 
B6 C57BL/6J mice 
CRC Colorectal carcinoma 
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i.v. Intravenous  
µg Microgram  
ml milliliter 
o/n Overnight  
PBS Phosphate buffered saline 
E:T Effector:target 
RT Room temperature 
FCS Fetal calf serum  
i.p. intraperitoneal 
min minutes 
mg milligram 
d day 
µm micrometer 
HRP Horseradish peroxidase 
DNA Deoxyribonucleic acid 
RNA Ribonucleic acid 
WTA Whole transcriptome amplification 
PNAs Peptide nucleic acids 
cm  centimeter 
CS Curative surgery  
MG Mammary gland  
Ca2+ Calcium 2+ 
MLR Mixed leukocyte reaction  
PT Primary tumor  
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